<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815424</url>
  </required_header>
  <id_info>
    <org_study_id>A3921174</org_study_id>
    <nct_id>NCT01815424</nct_id>
  </id_info>
  <brief_title>A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis</brief_title>
  <official_title>A PHASE 3, MULTI SITE, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF THE EFFICACY AND SAFETY OF 2 ORAL DOSES OF CP-690,550 IN ASIAN SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and 10
      mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks of
      treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are
      candidates for systemic therapy or phototherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Physician's Global Assessment (PGA) Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90% reduction in PASI relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DLQI Total Score at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PGA Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI75 Response at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DLQI Total Score at Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represent more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining PGA Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 52 Among Participants Achieving PGA Response at Week 16</measure>
    <time_frame>Week 16 to Week 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among patients achieving PGA response at Week 16 is reported. This is a key secondary endpoint. Percentage of participants maintaining the response and the 95% confidence interval (CI) were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16</measure>
    <time_frame>Week 16 to Week 52</time_frame>
    <description>The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response=at least 75% reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among patients achieving PASI75 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16</measure>
    <time_frame>Week 16 to Week 52</time_frame>
    <description>The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response=at least 90% reduction in PASI relative to Baseline. Maintenance of PASI90 response at Week 52 among patients achieving PASI90 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PGA Response up to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if less than 50% of participants had PGA response by Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PASI75 Response up to Week 16</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if less than 50% of participants had PASI50 response by Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PASI50 Response up to Week 16</measure>
    <time_frame>Baseline up to Week 16</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each PGA Category Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI75 Response Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual PASI Scores Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PASI Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI Component Scores Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of BSA&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PASI Component Scores Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in PASI Scores Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual BSA Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in BSA Over Time Through Week 52</measure>
    <time_frame>Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PASI50 Response Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI50 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PASI90 Response Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI90 response up to Week 52 is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With PASI125 Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline</measure>
    <time_frame>Baseline and Weeks 8, 16, 20, 32, 40, and 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline</measure>
    <time_frame>Baseline and weeks 8, 16, 20, 32, 40, and 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail was divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 8, 16, 20, 32, 40, and 52</time_frame>
    <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported. The total number of affected FINGER nails was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in NAPSI Over Time Through Week 52</measure>
    <time_frame>Baseline and weeks 8, 16, 20, 32, 40, and 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With NAPSI75 Response Over Time Through Week 52</measure>
    <time_frame>Weeks 8, 16, 20, 32, 40, and 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With NAPSI100 Response Over Time Through Week 52</measure>
    <time_frame>Weeks 8, 16, 20, 32, 40, and 52</time_frame>
    <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Itch Severity Item (ISI) Score Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in ISI Score Over Time Through Week 52</measure>
    <time_frame>Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DLQI Score Over Time Through Week 52</measure>
    <time_frame>Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Patient Global Assessment (PtGA) Response of &quot;Clear&quot; or &quot;Almost Clear&quot; Over Time Through Week 52</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
    <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe). the percentage of participants with scores of 0 (clear) and 1 (almost clear) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52</measure>
    <time_frame>Baseline, Weeks 16, 32, 40, 52</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D - Utility Score Over Time Through Week 52</measure>
    <time_frame>Baseline and weeks 16, 32, 40, and 52</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52</measure>
    <time_frame>Baseline and Weeks 16, 32, 40, and 52</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52</measure>
    <time_frame>Baseline and weeks 16, 32, 40, and 52</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) &lt;1.0 X 10^9/L (1000/mm^3); 2 sequential absolute lymphocyte counts &lt;0.5 X 10^9/L; 2 sequential hemoglobin values &lt;9.0 g/dL and/or decreases of &gt;30% from baseline value; 2 sequential platelet counts &lt;75 X 10^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine &gt;50% and an increase in serum creatinine &gt;0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations &gt;10X ULN.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) &lt;1.0 X 10^9/L (1000/mm^3); 2 sequential absolute lymphocyte counts &lt;0.5 X 10^9/L; 2 sequential hemoglobin values &lt;9.0 g/dL and/or decreases of &gt;30% from baseline value; 2 sequential platelet counts &lt;75 X 10^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine &gt;50% and an increase in serum creatinine &gt;0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations &gt;10X ULN.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (&lt;)40 or greater than (&gt;)120 beats per minute (bpm), heart rate less than (&lt;)40 or greater than (&gt;)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (&gt;=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP &lt;90 mmHg, sitting diastolic blood pressure (DBP) &gt;=20 mmHg change from baseline or sitting DBP &lt;50 mmHg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (&lt;)40 or greater than (&gt;)120 beats per minute (bpm), heart rate less than (&lt;)40 or greater than (&gt;)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (&gt;=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP &lt;90 mmHg, sitting diastolic blood pressure (DBP) &gt;=20 mmHg change from baseline or sitting DBP &lt;50 mmHg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty [PTCA], percutaneous coronary intervention [PCI], coronary bypass grafting [CABG], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-52</measure>
    <time_frame>Baseline up to Week 52</time_frame>
    <description>CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty [PTCA], percutaneous coronary intervention [PCI], coronary bypass grafting [CABG], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Adjudicated Malignancy Events Reported During Week 0-16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Adjudicated Malignancy Events Reported During Week 0-52</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Placebo BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5mg BID CP-690,550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg BID CP-690,550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo BID for 16 weeks and then re-randomized into active groups</description>
    <arm_group_label>Placebo BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>CP-690,550 5mg BID for 52 weeks</description>
    <arm_group_label>5mg BID CP-690,550</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>CP-690,550 10mg BID for 52 weeks</description>
    <arm_group_label>10mg BID CP-690,550</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have had a diagnosis of plaque-type psoriasis (psoriasis vulgaris) for at least 12
             months prior to the first screening procedure.

          -  Have a PASI score of 12 or greater AND a PGA score of 3 (&quot;moderate&quot;) or 4 (&quot;severe&quot;)
             at Baseline (Day 1).

          -  Considered by dermatologist investigator to be a candidate for systemic therapy or
             phototherapy of psoriasis (either naïve or history of previous treatment).

        Exclusion Criteria:

          -  Currently have non-plaque forms of psoriasis, eg, erythrodermic, guttate, or pustular
             psoriasis, with the exception of nail psoriasis which is allowed.

          -  Have current drug induced psoriasis, eg, a new onset of psoriasis or an exacerbation
             of psoriasis from beta blockers, calcium channel blockers, antimalarial drugs or
             lithium.

          -  Subjects who cannot discontinue systemic therapies and/or topical therapies for the
             treatment of psoriasis and cannot discontinue phototherapy (UVB or PUVA) for the study
             are excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. Of dermatology &amp;STD, Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Xicheng District</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of Skin Diseases, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210042</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, The Second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116027</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital, Fudan University/Dermatology Department</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital, Dermatology Department</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Department, The First Affiliated Hospital, The Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610031</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of College of Medicine, Zhejiang University/Dermatology and STD Dept</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital / The Department of Dermatology</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital/Dermatology Department</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital of the Ministry of Health/Department of Dermatology</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital/Department of Dermatology</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital, Dermatological Department</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology,Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>120-452</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cheng-Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation-Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921174&amp;StudyName=A%20Study%20Evaluating%20The%20Efficacy%20And%20Safety%20oO%20CP-690%2C550%20In%20Asian%20Subjects%20With%20Moderate%20To%20Severe%20Plaque%20Psoriasis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <results_first_submitted>July 11, 2016</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2019</results_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tofacitinib</keyword>
  <keyword>CP-690</keyword>
  <keyword>550</keyword>
  <keyword>Xeljanz</keyword>
  <keyword>Jak-Inhibitor</keyword>
  <keyword>Oral Treatment</keyword>
  <keyword>Psoriasis vulgaris</keyword>
  <keyword>Pruritus</keyword>
  <keyword>Itch</keyword>
  <keyword>DLQI</keyword>
  <keyword>moderate</keyword>
  <keyword>severe</keyword>
  <keyword>chronic</keyword>
  <keyword>plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tofacitinib 10 mg</title>
          <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
        </group>
        <group group_id="P2">
          <title>Tofacitinib 5 mg</title>
          <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
        </group>
        <group group_id="P4">
          <title>Placebo to Tofacitinib 10 mg</title>
          <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
        </group>
        <group group_id="P5">
          <title>Placebo to Tofacitinib 5 mg</title>
          <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Week 0 to 16</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Does Not Meet Entrance Criteria</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Week 16 to 52</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="38"/>
                <participants group_id="P5" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="35"/>
                <participants group_id="P5" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Insufficient Clinical Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Tofacitinib 10 mg</title>
          <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
        </group>
        <group group_id="B2">
          <title>Tofacitinib 5 mg</title>
          <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="88"/>
            <count group_id="B3" value="88"/>
            <count group_id="B4" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.0" spread="12.0"/>
                    <measurement group_id="B2" value="40.7" spread="11.3"/>
                    <measurement group_id="B3" value="41.7" spread="13.7"/>
                    <measurement group_id="B4" value="41.1" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Physician's Global Assessment (PGA) Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 16</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 16</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Non-Responder Imputation (NRI) method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Physician's Global Assessment (PGA) Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 16</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Non-Responder Imputation (NRI) method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.56"/>
                    <measurement group_id="O2" value="52.27"/>
                    <measurement group_id="O3" value="19.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for tofacitinib 10 mg vs placebo at Week 16; PASI75 response for tofacitinib 10 mg vs placebo at Week 16; PGA response for tofacitinib 5 mg vs placebo at Week 16; PASI75 response for tofacitinib 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>14.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.03</ci_lower_limit>
            <ci_upper_limit>32.77</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for tofacitinib 10 mg vs placebo at Week 16; PASI75 response for tofacitinib 10 mg vs placebo at Week 16; PGA response for tofacitinib 5 mg vs placebo at Week 16; PASI75 response for tofacitinib 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.46</ci_lower_limit>
            <ci_upper_limit>11.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to Baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least a 75% Reduction in PASI (PASI75) at Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least a 75% reduction in PASI relative to Baseline.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.11"/>
                    <measurement group_id="O2" value="54.55"/>
                    <measurement group_id="O3" value="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for tofacitinib 10 mg vs placebo at Week 16; PASI75 response for tofacitinib 10 mg vs placebo at Week 16; PGA response for tofacitinib 5 mg vs placebo at Week 16; PASI75 response for tofacitinib 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>41.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.84</ci_lower_limit>
            <ci_upper_limit>151.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>For primary endpoint, step-down procedure used to preserve Type I error, sequential order of testing: PGA response for tofacitinib 10 mg vs placebo at Week 16; PASI75 response for tofacitinib 10 mg vs placebo at Week 16; PGA response for tofacitinib 5 mg vs placebo at Week 16; PASI75 response for tofacitinib 5 mg vs placebo at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.05 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.06</ci_lower_limit>
            <ci_upper_limit>25.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16</title>
        <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed was the evaluable participants for the specific criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Total Body Surface Area (BSA) With Psoriasis at Week 16</title>
          <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed was the evaluable participants for the specific criteria.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.81" spread="5.903"/>
                    <measurement group_id="O2" value="-54.39" spread="5.838"/>
                    <measurement group_id="O3" value="-2.27" spread="6.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-71.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.461</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-88.20</ci_lower_limit>
            <ci_upper_limit>-54.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least Square Mean Difference</param_type>
            <param_value>-52.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>8.416</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.70</ci_lower_limit>
            <ci_upper_limit>-35.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90% reduction in PASI relative to Baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving at Least a 90% Reduction in PASI (PASI90) at Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both lesion severity and the percent of BSA affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response was defined as at least a 90% reduction in PASI relative to Baseline.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" spread="5.903"/>
                    <measurement group_id="O2" value="35.23" spread="5.838"/>
                    <measurement group_id="O3" value="3.41" spread="6.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>70.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.38</ci_lower_limit>
            <ci_upper_limit>267.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>16.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.31</ci_lower_limit>
            <ci_upper_limit>79.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DLQI Total Score at Week 16</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed was the evaluable participants for the specific criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DLQI Total Score at Week 16</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed was the evaluable participants for the specific criteria.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
                <count group_id="O2" value="84"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.10" spread="0.635"/>
                    <measurement group_id="O2" value="-7.03" spread="0.627"/>
                    <measurement group_id="O3" value="-1.57" spread="0.655"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16. This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-7.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.913</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.32</ci_lower_limit>
            <ci_upper_limit>5.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 16. This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-5.45</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.907</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.24</ci_lower_limit>
            <ci_upper_limit>-3.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PGA Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 4</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Week 4</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PGA Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 4</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" spread="0.497"/>
                    <measurement group_id="O2" value="19.32" spread="0.493"/>
                    <measurement group_id="O3" value="1.14" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant,only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>114.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>8.95</ci_lower_limit>
            <ci_upper_limit>2657.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>35.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.47</ci_lower_limit>
            <ci_upper_limit>1084.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI75 Response at Week 4</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.</description>
        <time_frame>Week 4</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI75 Response at Week 4</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44"/>
                    <measurement group_id="O2" value="4.55"/>
                    <measurement group_id="O3" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>OR and 95% CI not available due to 0% frequency in placebo group.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0386</p_value>
            <p_value_desc>Cochran-Mantel-Haenszel statistics adjusted for pooled investigator sites was used for the analysis. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>OR and 95% CI not available due to 0% frequency in placebo group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DLQI Total Score at Week 4</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline to Week 4</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed was the evaluable participants for the specific criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DLQI Total Score at Week 4</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed was the evaluable participants for the specific criteria.</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.03" spread="0.497"/>
                    <measurement group_id="O2" value="-5.14" spread="0.493"/>
                    <measurement group_id="O3" value="-0.94" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4. This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-5.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.709</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.49</ci_lower_limit>
            <ci_upper_limit>-3.70</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Week 4. This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean difference</param_type>
            <param_value>-4.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.706</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.59</ci_lower_limit>
            <ci_upper_limit>-2.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represent more severe psoriasis.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed signifies those participants who were evaluable (had nail psoriasis at Baseline and had at least one measurement during follow up) for this measure..</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Nail Psorasis Severity Index (NAPSI) at Week 16 in Participants With Nail Psoriasis at Baseline</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represent more severe psoriasis.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. Number of participants analyzed signifies those participants who were evaluable (had nail psoriasis at Baseline and had at least one measurement during follow up) for this measure..</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.32" spread="10.518"/>
                    <measurement group_id="O2" value="-14.98" spread="10.566"/>
                    <measurement group_id="O3" value="7.91" spread="12.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0113</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean of difference</param_type>
            <param_value>-41.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.977</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.91</ci_lower_limit>
            <ci_upper_limit>-9.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>This is a key secondary endpoint; family-wise step-down procedure was used to control Type I error. Sequential order of testing: percent change in BSA at Week 16, PASI90 response at Week 16, change in DLQI total score at Week 16, PGA response at Week 4, PASI75 at Week 4, change in DLQI total score at Week 4, percent change in NAPSI score at Week 16. If comparison at preceding step was significant, only then subsequent comparison was tested at the below specified significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1558</p_value>
            <p_value_desc>Mixed model with fixed effects for treatment, visit, treatment-by-visit interaction, baseline value, and a random effect of subject; unstructured covariance matrix was used. Each hypothesis was tested at a significance level of 0.025 (2-sided).</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Least square mean of difference</param_type>
            <param_value>-22.89</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>16.010</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-54.64</ci_lower_limit>
            <ci_upper_limit>8.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining PGA Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 52 Among Participants Achieving PGA Response at Week 16</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among patients achieving PGA response at Week 16 is reported. This is a key secondary endpoint. Percentage of participants maintaining the response and the 95% confidence interval (CI) were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
        <time_frame>Week 16 to Week 52</time_frame>
        <population>Patients in the full analysis population and those who had PGA response at Week 16 and non-missing post Week 16 data were included. Patients initially treated with placebo were not included as they were advanced to tofacitinib and this maintaining response at Week 52 was not relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining PGA Score of &quot;Clear&quot; or &quot;Almost Clear&quot; at Week 52 Among Participants Achieving PGA Response at Week 16</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Maintenance of PGA response at Week 52 among patients achieving PGA response at Week 16 is reported. This is a key secondary endpoint. Percentage of participants maintaining the response and the 95% confidence interval (CI) were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
          <population>Patients in the full analysis population and those who had PGA response at Week 16 and non-missing post Week 16 data were included. Patients initially treated with placebo were not included as they were advanced to tofacitinib and this maintaining response at Week 52 was not relevant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" spread="0.497" lower_limit="62.91" upper_limit="83.65"/>
                    <measurement group_id="O2" value="73.63" spread="0.493" lower_limit="58.24" upper_limit="84.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16</title>
        <description>The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response=at least 75% reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among patients achieving PASI75 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
        <time_frame>Week 16 to Week 52</time_frame>
        <population>Patients in the full analysis population and those who had PASI75 response at Week 16 and non-missing post Week 16 data were included. Patients initially treated with placebo were not included as they were advanced to tofacitinib and this maintaining response at Week 52 was not relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining PASI75 Response at Week 52 Among Participants Achieving PASI75 Response at Week 16</title>
          <description>The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response=at least 75% reduction in PASI relative to Baseline. Maintenance of PASI75 response at Week 52 among patients achieving PASI75 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
          <population>Patients in the full analysis population and those who had PASI75 response at Week 16 and non-missing post Week 16 data were included. Patients initially treated with placebo were not included as they were advanced to tofacitinib and this maintaining response at Week 52 was not relevant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.93" spread="0.497" lower_limit="74.44" upper_limit="91.36"/>
                    <measurement group_id="O2" value="76.82" spread="0.493" lower_limit="62.04" upper_limit="86.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16</title>
        <description>The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response=at least 90% reduction in PASI relative to Baseline. Maintenance of PASI90 response at Week 52 among patients achieving PASI90 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
        <time_frame>Week 16 to Week 52</time_frame>
        <population>Patients in the full analysis population and those who had PASI90 response at Week 16 and non-missing post Week 16 data were included. Patients initially treated with placebo were not included as they were advanced to tofacitinib and this maintaining response at Week 52 was not relevant.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Maintaining PASI90 Response at Week 52 Among Participants Achieving PASI90 at Week 16</title>
          <description>The PASI quantifies severity of a participant's psoriasis based on both lesion severity and percent of BSA affected. PASI is a composite scoring by investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk including axillae and groin, and lower limbs including buttocks), with adjustment for percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI90 response=at least 90% reduction in PASI relative to Baseline. Maintenance of PASI90 response at Week 52 among patients achieving PASI90 response at Week 16 is reported. This is a key secondary endpoint. Probability and the 95% CI were estimated based on the Kaplan-Meier method. Event is loss of response. Percentage of maintaining response is (1-probability of loss of response).</description>
          <population>Patients in the full analysis population and those who had PASI90 response at Week 16 and non-missing post Week 16 data were included. Patients initially treated with placebo were not included as they were advanced to tofacitinib and this maintaining response at Week 52 was not relevant.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.07" spread="0.497" lower_limit="60.19" upper_limit="83.75"/>
                    <measurement group_id="O2" value="70.45" spread="0.493" lower_limit="50.85" upper_limit="83.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PGA Response up to Week 16</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if less than 50% of participants had PGA response by Week 16.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>Participants with non-missing post-baseline response data in the full analysis population (all participants who were randomized to the study and received at least 1 dose of study drug) were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PGA Response up to Week 16</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). Median time to achieve a PGA response up to week 16 is reported. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 1). Median time to event is not estimable if less than 50% of participants had PGA response by Week 16.</description>
          <population>Participants with non-missing post-baseline response data in the full analysis population (all participants who were randomized to the study and received at least 1 dose of study drug) were included.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="14.0" lower_limit="12.0" upper_limit="NA">Upper limit of the CI is not estimable. The time frame from Baseline to Week 16 is insufficient to observe the required number of responders for the upper limit.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable. Less than half of the participants are responders by Week 16 (ie. censoring percent is &gt;50%).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PASI75 Response up to Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if less than 50% of participants had PASI50 response by Week 16.</description>
        <time_frame>Baseline up to Week 16</time_frame>
        <population>Participants with non-missing post-baseline responses data in the full analysis population (all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo) were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PASI75 Response up to Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI75 response was defined as at least 75% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 2). Median time to event is not estimable if less than 50% of participants had PASI50 response by Week 16.</description>
          <population>Participants with non-missing post-baseline responses data in the full analysis population (all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo) were included.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="16.0" lower_limit="12.0" upper_limit="NA">Upper limit of the CI is not estimable. The time frame from Baseline to Week 16 is insufficient to observe the required number of responders for the upper limit.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable. Less than half of the participants are responders by Week 16 (ie. censoring percent is &gt;50%).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PASI50 Response up to Week 16</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
        <time_frame>Baseline up to Week 16</time_frame>
        <population>Participants with non-missing post-baseline responses data in the full analysis population (all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo) were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PASI50 Response up to Week 16</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. The median time to event was estimated based on the probability of event-rate based on life table estimates (not the observed rate as in outcome measure 26). Median time to event is not estimable if the estimated probability of response by Week 16 is less than 50%.</description>
          <population>Participants with non-missing post-baseline responses data in the full analysis population (all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo) were included.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="4.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="8.0" lower_limit="8.0" upper_limit="12.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Not estimable. Less than half of the participants are responders by Week 16 (ie. censoring percent is &gt;50%).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PGA Response of 'Clear' or 'Almost Clear' Over Time Through Week 52</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear).</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="0.00" upper_limit="7.04"/>
                    <measurement group_id="O2" value="2.27" lower_limit="0.00" upper_limit="5.39"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.78" lower_limit="27.76" upper_limit="47.79"/>
                    <measurement group_id="O2" value="19.32" lower_limit="11.07" upper_limit="27.57"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.78" lower_limit="47.57" upper_limit="67.98"/>
                    <measurement group_id="O2" value="38.64" lower_limit="28.46" upper_limit="48.81"/>
                    <measurement group_id="O3" value="11.36" lower_limit="1.99" upper_limit="20.74"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.44" lower_limit="65.43" upper_limit="83.46"/>
                    <measurement group_id="O2" value="50.00" lower_limit="39.55" upper_limit="60.45"/>
                    <measurement group_id="O3" value="25.00" lower_limit="12.21" upper_limit="37.79"/>
                    <measurement group_id="O4" value="6.82" lower_limit="0.00" upper_limit="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.56" lower_limit="66.68" upper_limit="84.43"/>
                    <measurement group_id="O2" value="52.27" lower_limit="41.84" upper_limit="62.71"/>
                    <measurement group_id="O3" value="29.55" lower_limit="16.06" upper_limit="43.03"/>
                    <measurement group_id="O4" value="9.09" lower_limit="0.60" upper_limit="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.56" lower_limit="66.68" upper_limit="84.43"/>
                    <measurement group_id="O2" value="54.55" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="59.09" lower_limit="44.56" upper_limit="73.62"/>
                    <measurement group_id="O4" value="47.73" lower_limit="32.97" upper_limit="62.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.33" lower_limit="64.20" upper_limit="82.47"/>
                    <measurement group_id="O2" value="53.41" lower_limit="42.99" upper_limit="63.83"/>
                    <measurement group_id="O3" value="68.18" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="52.27" lower_limit="37.51" upper_limit="67.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.22" lower_limit="62.97" upper_limit="81.48"/>
                    <measurement group_id="O2" value="55.68" lower_limit="45.30" upper_limit="66.06"/>
                    <measurement group_id="O3" value="65.91" lower_limit="51.90" upper_limit="79.92"/>
                    <measurement group_id="O4" value="54.55" lower_limit="39.83" upper_limit="69.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.78" lower_limit="58.12" upper_limit="77.43"/>
                    <measurement group_id="O2" value="54.55" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="59.09" lower_limit="44.56" upper_limit="73.62"/>
                    <measurement group_id="O4" value="50.00" lower_limit="35.23" upper_limit="64.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each PGA Category Over Time Through Week 52</title>
        <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each PGA Category Over Time Through Week 52</title>
          <description>The PGA of psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling are scored separately over the whole body according to a 5-point severity scale (0 [no symptom] to 4 [severe symptom]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). Percentage of participants with each PGA score is reported.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; n=number of evaluable participants at the specified time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Clear (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="95.67" upper_limit="100.0"/>
                    <measurement group_id="O2" value="0" lower_limit="83.16" upper_limit="99.45"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Almost Clear (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mild (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Moderate (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.6"/>
                    <measurement group_id="O2" value="87.5"/>
                    <measurement group_id="O3" value="81.8"/>
                    <measurement group_id="O4" value="70.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Severe (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="18.2"/>
                    <measurement group_id="O4" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Clear (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Almost Clear (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Mild (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7"/>
                    <measurement group_id="O2" value="36.0"/>
                    <measurement group_id="O3" value="11.4"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Moderate (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="55.8"/>
                    <measurement group_id="O3" value="75.0"/>
                    <measurement group_id="O4" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Severe (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="13.6"/>
                    <measurement group_id="O4" value="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Clear (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3"/>
                    <measurement group_id="O2" value="1.1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Almost Clear (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="2.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Mild (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="39.8"/>
                    <measurement group_id="O3" value="23.3"/>
                    <measurement group_id="O4" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Moderate (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.6"/>
                    <measurement group_id="O2" value="36.4"/>
                    <measurement group_id="O3" value="53.5"/>
                    <measurement group_id="O4" value="69.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Severe (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="20.9"/>
                    <measurement group_id="O4" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Clear (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="3.4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Almost Clear (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.6"/>
                    <measurement group_id="O2" value="35.2"/>
                    <measurement group_id="O3" value="12.5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Mild (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="30.0"/>
                    <measurement group_id="O4" value="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Moderate (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="30.7"/>
                    <measurement group_id="O3" value="42.5"/>
                    <measurement group_id="O4" value="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Severe (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="15.0"/>
                    <measurement group_id="O4" value="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Clear (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Almost Clear (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.2"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="27.5"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Mild (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="30.0"/>
                    <measurement group_id="O4" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Moderate (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="22.7"/>
                    <measurement group_id="O3" value="37.5"/>
                    <measurement group_id="O4" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Severe (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.0"/>
                    <measurement group_id="O4" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Clear (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Almost Clear (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1"/>
                    <measurement group_id="O2" value="38.1"/>
                    <measurement group_id="O3" value="28.9"/>
                    <measurement group_id="O4" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Mild (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="21.4"/>
                    <measurement group_id="O3" value="26.3"/>
                    <measurement group_id="O4" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Moderate (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="23.8"/>
                    <measurement group_id="O3" value="34.2"/>
                    <measurement group_id="O4" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Severe (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5.3"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Clear (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="15.8"/>
                    <measurement group_id="O4" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Almost Clear (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0"/>
                    <measurement group_id="O2" value="32.1"/>
                    <measurement group_id="O3" value="52.6"/>
                    <measurement group_id="O4" value="51.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Mild (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9"/>
                    <measurement group_id="O2" value="29.8"/>
                    <measurement group_id="O3" value="18.4"/>
                    <measurement group_id="O4" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Moderate (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="13.1"/>
                    <measurement group_id="O3" value="13.2"/>
                    <measurement group_id="O4" value="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Severe (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Clear (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8"/>
                    <measurement group_id="O2" value="31.3"/>
                    <measurement group_id="O3" value="44.7"/>
                    <measurement group_id="O4" value="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Almost Clear (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="34.2"/>
                    <measurement group_id="O4" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Mild (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="18.4"/>
                    <measurement group_id="O4" value="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Moderate (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="16.9"/>
                    <measurement group_id="O3" value="2.6"/>
                    <measurement group_id="O4" value="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Severe (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Clear (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                    <measurement group_id="O2" value="29.6"/>
                    <measurement group_id="O3" value="48.6"/>
                    <measurement group_id="O4" value="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Almost Clear (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.2"/>
                    <measurement group_id="O2" value="30.9"/>
                    <measurement group_id="O3" value="29.7"/>
                    <measurement group_id="O4" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Mild (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="25.9"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Moderate (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="13.6"/>
                    <measurement group_id="O3" value="8.1"/>
                    <measurement group_id="O4" value="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Severe (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Clear (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Almost Clear (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Mild (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Moderate (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5"/>
                    <measurement group_id="O2" value="17.9"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Severe (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI75 Response Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI75 Response Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 75 response was defined as at least 75% reduction in PASI relative to Baseline. Percentage of participants with PASI 75 response is reported.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.00" upper_limit="3.28"/>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.44" lower_limit="15.57" upper_limit="33.32"/>
                    <measurement group_id="O2" value="4.55" lower_limit="0.19" upper_limit="8.90"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.11" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="31.82" lower_limit="22.09" upper_limit="41.55"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.22" lower_limit="62.97" upper_limit="81.48"/>
                    <measurement group_id="O2" value="47.73" lower_limit="37.29" upper_limit="58.16"/>
                    <measurement group_id="O3" value="11.36" lower_limit="1.99" upper_limit="20.74"/>
                    <measurement group_id="O4" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.11" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="54.55" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="20.45" lower_limit="8.54" upper_limit="32.37"/>
                    <measurement group_id="O4" value="4.55" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" lower_limit="75.63" upper_limit="91.03"/>
                    <measurement group_id="O2" value="54.55" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="52.27" lower_limit="37.51" upper_limit="67.03"/>
                    <measurement group_id="O4" value="27.27" lower_limit="14.11" upper_limit="40.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.11" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="59.09" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="75.00" lower_limit="62.21" upper_limit="87.79"/>
                    <measurement group_id="O4" value="65.91" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00" lower_limit="71.74" upper_limit="88.26"/>
                    <measurement group_id="O2" value="56.82" lower_limit="46.47" upper_limit="67.17"/>
                    <measurement group_id="O3" value="68.18" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="65.91" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.67" lower_limit="67.93" upper_limit="85.40"/>
                    <measurement group_id="O2" value="59.09" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="63.64" lower_limit="49.42" upper_limit="77.85"/>
                    <measurement group_id="O4" value="59.09" lower_limit="44.56" upper_limit="73.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual PASI Scores Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual PASI Scores Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.34" spread="9.106" lower_limit="0.00" upper_limit="3.28"/>
                    <measurement group_id="O2" value="25.32" spread="10.185" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="25.62" spread="10.429" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="26.51" spread="8.525" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.03" spread="9.392" lower_limit="15.57" upper_limit="33.32"/>
                    <measurement group_id="O2" value="21.23" spread="9.979" lower_limit="0.19" upper_limit="8.90"/>
                    <measurement group_id="O3" value="25.72" spread="10.582" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="26.34" spread="9.456" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.81" spread="9.826" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="17.41" spread="10.565" lower_limit="22.09" upper_limit="41.55"/>
                    <measurement group_id="O3" value="24.81" spread="12.081" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="24.65" spread="9.433" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" spread="9.075" lower_limit="62.97" upper_limit="81.48"/>
                    <measurement group_id="O2" value="12.56" spread="10.623" lower_limit="37.29" upper_limit="58.16"/>
                    <measurement group_id="O3" value="21.38" spread="11.689" lower_limit="1.99" upper_limit="20.74"/>
                    <measurement group_id="O4" value="22.46" spread="8.966" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.56" spread="6.979" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="10.10" spread="9.858" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="17.83" spread="10.503" lower_limit="8.54" upper_limit="32.37"/>
                    <measurement group_id="O4" value="21.35" spread="9.477" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.48" spread="6.722" lower_limit="75.63" upper_limit="91.03"/>
                    <measurement group_id="O2" value="8.42" spread="9.800" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="15.27" spread="11.441" lower_limit="37.51" upper_limit="67.03"/>
                    <measurement group_id="O4" value="20.64" spread="9.738" lower_limit="14.11" upper_limit="40.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="5.610" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="7.13" spread="8.280" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="6.52" spread="6.512" lower_limit="62.21" upper_limit="87.79"/>
                    <measurement group_id="O4" value="10.43" spread="7.612" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="3.810" lower_limit="71.74" upper_limit="88.26"/>
                    <measurement group_id="O2" value="6.23" spread="7.817" lower_limit="46.47" upper_limit="67.17"/>
                    <measurement group_id="O3" value="3.09" spread="5.434" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="4.82" spread="5.517" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="3.553" lower_limit="67.93" upper_limit="85.40"/>
                    <measurement group_id="O2" value="5.74" spread="6.415" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="2.79" spread="4.458" lower_limit="49.42" upper_limit="77.85"/>
                    <measurement group_id="O4" value="3.74" spread="4.540" lower_limit="44.56" upper_limit="73.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.82" spread="4.674"/>
                    <measurement group_id="O2" value="6.00" spread="7.313"/>
                    <measurement group_id="O3" value="3.11" spread="5.027"/>
                    <measurement group_id="O4" value="4.69" spread="4.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PASI Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PASI Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.40" spread="6.724" lower_limit="15.57" upper_limit="33.32"/>
                    <measurement group_id="O2" value="-4.26" spread="5.231" lower_limit="0.19" upper_limit="8.90"/>
                    <measurement group_id="O3" value="0.10" spread="4.715" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="-0.04" spread="3.676" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.74" spread="8.528" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="-7.91" spread="7.053" lower_limit="22.09" upper_limit="41.55"/>
                    <measurement group_id="O3" value="-0.76" spread="7.423" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="-1.72" spread="3.799" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.25" spread="10.244" lower_limit="62.97" upper_limit="81.48"/>
                    <measurement group_id="O2" value="-12.76" spread="10.033" lower_limit="37.29" upper_limit="58.16"/>
                    <measurement group_id="O3" value="-4.25" spread="8.996" lower_limit="1.99" upper_limit="20.74"/>
                    <measurement group_id="O4" value="-4.51" spread="6.130" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.98" spread="9.612" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="-15.22" spread="11.214" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="-7.71" spread="10.717" lower_limit="8.54" upper_limit="32.37"/>
                    <measurement group_id="O4" value="-5.62" spread="7.169" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.07" spread="10.127" lower_limit="75.63" upper_limit="91.03"/>
                    <measurement group_id="O2" value="-17.12" spread="11.711" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="-10.03" spread="12.976" lower_limit="37.51" upper_limit="67.03"/>
                    <measurement group_id="O4" value="-6.33" spread="8.973" lower_limit="14.11" upper_limit="40.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.79" spread="9.675" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="-18.42" spread="10.955" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="-18.79" spread="12.428" lower_limit="62.21" upper_limit="87.79"/>
                    <measurement group_id="O4" value="-16.54" spread="8.732" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.45" spread="9.369" lower_limit="71.74" upper_limit="88.26"/>
                    <measurement group_id="O2" value="-19.45" spread="10.312" lower_limit="46.47" upper_limit="67.17"/>
                    <measurement group_id="O3" value="-22.22" spread="11.550" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="-21.86" spread="9.283" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.47" spread="9.702" lower_limit="67.93" upper_limit="85.40"/>
                    <measurement group_id="O2" value="-20.11" spread="10.292" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="-22.80" spread="11.268" lower_limit="49.42" upper_limit="77.85"/>
                    <measurement group_id="O4" value="-22.94" spread="9.512" lower_limit="44.56" upper_limit="73.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.71" spread="10.655"/>
                    <measurement group_id="O2" value="-20.04" spread="10.819"/>
                    <measurement group_id="O3" value="-22.54" spread="12.368"/>
                    <measurement group_id="O4" value="-22.00" spread="9.429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PASI Component Scores Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of BSA&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>PASI Component Scores Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of BSA&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Erythema (Head/Neck) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.830" lower_limit="15.57" upper_limit="33.32"/>
                    <measurement group_id="O2" value="2.18" spread="0.977" lower_limit="0.19" upper_limit="8.90"/>
                    <measurement group_id="O3" value="2.18" spread="1.018" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="2.39" spread="0.868" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Head/Neck) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.74" spread="0.903" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="1.77" spread="1.037" lower_limit="22.09" upper_limit="41.55"/>
                    <measurement group_id="O3" value="2.05" spread="1.033" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="2.50" spread="0.834" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Head/Neck) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.978" lower_limit="62.97" upper_limit="81.48"/>
                    <measurement group_id="O2" value="1.44" spread="1.015" lower_limit="37.29" upper_limit="58.16"/>
                    <measurement group_id="O3" value="1.91" spread="1.065" lower_limit="1.99" upper_limit="20.74"/>
                    <measurement group_id="O4" value="2.24" spread="0.726" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Head/Neck) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.997" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="1.14" spread="1.052" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="1.93" spread="1.141" lower_limit="8.54" upper_limit="32.37"/>
                    <measurement group_id="O4" value="2.05" spread="1.075" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Head/Neck) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.867" lower_limit="75.63" upper_limit="91.03"/>
                    <measurement group_id="O2" value="0.94" spread="1.065" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="1.75" spread="1.171" lower_limit="37.51" upper_limit="67.03"/>
                    <measurement group_id="O4" value="1.97" spread="1.038" lower_limit="14.11" upper_limit="40.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.839" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="0.82" spread="1.032" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="1.47" spread="1.156" lower_limit="62.21" upper_limit="87.79"/>
                    <measurement group_id="O4" value="1.82" spread="1.073" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.784" lower_limit="71.74" upper_limit="88.26"/>
                    <measurement group_id="O2" value="0.82" spread="0.971" lower_limit="46.47" upper_limit="67.17"/>
                    <measurement group_id="O3" value="0.76" spread="0.883" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="1.08" spread="0.839" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Head/Neck) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.885" lower_limit="67.93" upper_limit="85.40"/>
                    <measurement group_id="O2" value="0.73" spread="0.989" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="0.45" spread="0.860" lower_limit="49.42" upper_limit="77.85"/>
                    <measurement group_id="O4" value="0.84" spread="1.041" lower_limit="44.56" upper_limit="73.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Head/Neck) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.882"/>
                    <measurement group_id="O2" value="0.74" spread="0.946"/>
                    <measurement group_id="O3" value="0.43" spread="0.728"/>
                    <measurement group_id="O4" value="0.64" spread="0.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Head/Neck) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.925"/>
                    <measurement group_id="O2" value="0.72" spread="0.966"/>
                    <measurement group_id="O3" value="0.47" spread="0.774"/>
                    <measurement group_id="O4" value="0.78" spread="0.929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Erythema (Upper Limbs) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.694"/>
                    <measurement group_id="O2" value="2.78" spread="0.686"/>
                    <measurement group_id="O3" value="2.66" spread="0.805"/>
                    <measurement group_id="O4" value="2.73" spread="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Upper Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.06" spread="0.793"/>
                    <measurement group_id="O2" value="2.28" spread="0.792"/>
                    <measurement group_id="O3" value="2.68" spread="0.829"/>
                    <measurement group_id="O4" value="2.90" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Upper Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="0.826"/>
                    <measurement group_id="O2" value="1.88" spread="0.920"/>
                    <measurement group_id="O3" value="2.53" spread="0.960"/>
                    <measurement group_id="O4" value="2.71" spread="0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Upper Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.937"/>
                    <measurement group_id="O2" value="1.47" spread="0.982"/>
                    <measurement group_id="O3" value="2.35" spread="1.075"/>
                    <measurement group_id="O4" value="2.51" spread="0.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Upper Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" spread="0.778"/>
                    <measurement group_id="O2" value="1.17" spread="1.074"/>
                    <measurement group_id="O3" value="2.13" spread="1.067"/>
                    <measurement group_id="O4" value="2.36" spread="0.873"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.784"/>
                    <measurement group_id="O2" value="0.99" spread="1.024"/>
                    <measurement group_id="O3" value="1.71" spread="1.137"/>
                    <measurement group_id="O4" value="2.33" spread="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.793"/>
                    <measurement group_id="O2" value="0.93" spread="0.967"/>
                    <measurement group_id="O3" value="0.97" spread="0.788"/>
                    <measurement group_id="O4" value="1.38" spread="0.877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Upper Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.697"/>
                    <measurement group_id="O2" value="0.96" spread="1.087"/>
                    <measurement group_id="O3" value="0.55" spread="0.760"/>
                    <measurement group_id="O4" value="0.86" spread="1.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Upper Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.791"/>
                    <measurement group_id="O2" value="0.93" spread="1.034"/>
                    <measurement group_id="O3" value="0.59" spread="0.927"/>
                    <measurement group_id="O4" value="0.78" spread="0.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Upper Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.939"/>
                    <measurement group_id="O2" value="0.95" spread="1.031"/>
                    <measurement group_id="O3" value="0.69" spread="0.980"/>
                    <measurement group_id="O4" value="0.89" spread="1.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Erythema (Trunk) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="0.696"/>
                    <measurement group_id="O2" value="2.81" spread="0.658"/>
                    <measurement group_id="O3" value="2.86" spread="0.510"/>
                    <measurement group_id="O4" value="2.93" spread="0.625"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Trunk) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.830"/>
                    <measurement group_id="O2" value="2.44" spread="0.776"/>
                    <measurement group_id="O3" value="2.84" spread="0.568"/>
                    <measurement group_id="O4" value="3.05" spread="0.697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Trunk) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.82" spread="0.922"/>
                    <measurement group_id="O2" value="2.05" spread="0.883"/>
                    <measurement group_id="O3" value="2.72" spread="0.734"/>
                    <measurement group_id="O4" value="2.83" spread="0.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Trunk) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.20" spread="1.056"/>
                    <measurement group_id="O2" value="1.65" spread="1.006"/>
                    <measurement group_id="O3" value="2.50" spread="0.987"/>
                    <measurement group_id="O4" value="2.64" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Trunk) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="1.024"/>
                    <measurement group_id="O2" value="1.44" spread="1.133"/>
                    <measurement group_id="O3" value="2.20" spread="1.137"/>
                    <measurement group_id="O4" value="2.54" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.929"/>
                    <measurement group_id="O2" value="1.21" spread="1.173"/>
                    <measurement group_id="O3" value="1.87" spread="1.234"/>
                    <measurement group_id="O4" value="2.64" spread="0.811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.005"/>
                    <measurement group_id="O2" value="1.12" spread="1.080"/>
                    <measurement group_id="O3" value="1.08" spread="0.997"/>
                    <measurement group_id="O4" value="1.31" spread="0.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Trunk) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.952"/>
                    <measurement group_id="O2" value="1.02" spread="1.137"/>
                    <measurement group_id="O3" value="0.53" spread="0.893"/>
                    <measurement group_id="O4" value="0.70" spread="0.968"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Trunk) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.823"/>
                    <measurement group_id="O2" value="0.96" spread="1.078"/>
                    <measurement group_id="O3" value="0.43" spread="0.835"/>
                    <measurement group_id="O4" value="0.67" spread="0.862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Trunk) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="0.924"/>
                    <measurement group_id="O2" value="0.99" spread="1.099"/>
                    <measurement group_id="O3" value="0.64" spread="1.073"/>
                    <measurement group_id="O4" value="0.92" spread="0.937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Erythema (Lower Limbs) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.678"/>
                    <measurement group_id="O2" value="2.98" spread="0.660"/>
                    <measurement group_id="O3" value="3.05" spread="0.746"/>
                    <measurement group_id="O4" value="3.16" spread="0.608"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Lower Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="0.870"/>
                    <measurement group_id="O2" value="2.60" spread="0.830"/>
                    <measurement group_id="O3" value="3.05" spread="0.776"/>
                    <measurement group_id="O4" value="3.24" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Lower Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="0.946"/>
                    <measurement group_id="O2" value="2.23" spread="0.854"/>
                    <measurement group_id="O3" value="2.93" spread="0.856"/>
                    <measurement group_id="O4" value="3.07" spread="0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Lower Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.33" spread="1.051"/>
                    <measurement group_id="O2" value="1.78" spread="1.077"/>
                    <measurement group_id="O3" value="2.70" spread="0.939"/>
                    <measurement group_id="O4" value="2.92" spread="0.739"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Lower Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" spread="0.865"/>
                    <measurement group_id="O2" value="1.53" spread="1.082"/>
                    <measurement group_id="O3" value="2.48" spread="1.012"/>
                    <measurement group_id="O4" value="2.82" spread="0.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.883"/>
                    <measurement group_id="O2" value="1.44" spread="1.155"/>
                    <measurement group_id="O3" value="2.13" spread="1.166"/>
                    <measurement group_id="O4" value="2.77" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.870"/>
                    <measurement group_id="O2" value="1.26" spread="1.043"/>
                    <measurement group_id="O3" value="1.16" spread="0.945"/>
                    <measurement group_id="O4" value="1.77" spread="0.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Lower Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.860"/>
                    <measurement group_id="O2" value="1.13" spread="1.197"/>
                    <measurement group_id="O3" value="0.66" spread="0.909"/>
                    <measurement group_id="O4" value="1.11" spread="1.100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Lower Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.963"/>
                    <measurement group_id="O2" value="1.14" spread="1.159"/>
                    <measurement group_id="O3" value="0.70" spread="0.968"/>
                    <measurement group_id="O4" value="0.81" spread="0.889"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Lower Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="1.024"/>
                    <measurement group_id="O2" value="1.24" spread="1.281"/>
                    <measurement group_id="O3" value="0.78" spread="1.198"/>
                    <measurement group_id="O4" value="0.94" spread="1.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration (Head/Neck) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.937"/>
                    <measurement group_id="O2" value="1.94" spread="0.998"/>
                    <measurement group_id="O3" value="2.07" spread="1.065"/>
                    <measurement group_id="O4" value="2.20" spread="0.930"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Head/Neck) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="0.998"/>
                    <measurement group_id="O2" value="1.67" spread="1.011"/>
                    <measurement group_id="O3" value="2.00" spread="1.100"/>
                    <measurement group_id="O4" value="2.19" spread="0.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Head/Neck) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" spread="1.022"/>
                    <measurement group_id="O2" value="1.35" spread="1.073"/>
                    <measurement group_id="O3" value="1.74" spread="1.071"/>
                    <measurement group_id="O4" value="2.10" spread="0.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Head/Neck) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" spread="1.010"/>
                    <measurement group_id="O2" value="1.08" spread="1.074"/>
                    <measurement group_id="O3" value="1.55" spread="0.959"/>
                    <measurement group_id="O4" value="1.92" spread="1.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Head/Neck) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.847"/>
                    <measurement group_id="O2" value="0.86" spread="1.008"/>
                    <measurement group_id="O3" value="1.40" spread="0.900"/>
                    <measurement group_id="O4" value="1.72" spread="0.972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.736"/>
                    <measurement group_id="O2" value="0.73" spread="0.974"/>
                    <measurement group_id="O3" value="1.29" spread="0.984"/>
                    <measurement group_id="O4" value="1.56" spread="0.995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.642"/>
                    <measurement group_id="O2" value="0.67" spread="0.910"/>
                    <measurement group_id="O3" value="0.58" spread="0.683"/>
                    <measurement group_id="O4" value="0.90" spread="0.718"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Head/Neck) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.755"/>
                    <measurement group_id="O2" value="0.57" spread="0.814"/>
                    <measurement group_id="O3" value="0.32" spread="0.702"/>
                    <measurement group_id="O4" value="0.62" spread="0.794"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Head/Neck) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.742"/>
                    <measurement group_id="O2" value="0.60" spread="0.801"/>
                    <measurement group_id="O3" value="0.35" spread="0.633"/>
                    <measurement group_id="O4" value="0.53" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Head/Neck) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.871"/>
                    <measurement group_id="O2" value="0.60" spread="0.888"/>
                    <measurement group_id="O3" value="0.44" spread="0.735"/>
                    <measurement group_id="O4" value="0.61" spread="0.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration (Upper Limbs) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="0.738"/>
                    <measurement group_id="O2" value="2.59" spread="0.783"/>
                    <measurement group_id="O3" value="2.57" spread="0.925"/>
                    <measurement group_id="O4" value="2.77" spread="0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Upper Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.02" spread="0.884"/>
                    <measurement group_id="O2" value="2.16" spread="0.919"/>
                    <measurement group_id="O3" value="2.52" spread="0.876"/>
                    <measurement group_id="O4" value="2.74" spread="0.798"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Upper Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="1.054"/>
                    <measurement group_id="O2" value="1.82" spread="1.012"/>
                    <measurement group_id="O3" value="2.35" spread="1.021"/>
                    <measurement group_id="O4" value="2.62" spread="0.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Upper Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.01" spread="1.029"/>
                    <measurement group_id="O2" value="1.40" spread="1.078"/>
                    <measurement group_id="O3" value="2.03" spread="1.050"/>
                    <measurement group_id="O4" value="2.36" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Upper Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.813"/>
                    <measurement group_id="O2" value="1.13" spread="1.081"/>
                    <measurement group_id="O3" value="1.78" spread="1.000"/>
                    <measurement group_id="O4" value="2.23" spread="0.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.761"/>
                    <measurement group_id="O2" value="1.05" spread="1.108"/>
                    <measurement group_id="O3" value="1.55" spread="1.083"/>
                    <measurement group_id="O4" value="2.08" spread="0.870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.818"/>
                    <measurement group_id="O2" value="0.90" spread="1.013"/>
                    <measurement group_id="O3" value="0.89" spread="0.924"/>
                    <measurement group_id="O4" value="1.18" spread="0.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Upper Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="0.798"/>
                    <measurement group_id="O2" value="0.96" spread="1.064"/>
                    <measurement group_id="O3" value="0.58" spread="0.919"/>
                    <measurement group_id="O4" value="0.78" spread="0.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Upper Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.867"/>
                    <measurement group_id="O2" value="0.94" spread="1.041"/>
                    <measurement group_id="O3" value="0.49" spread="0.768"/>
                    <measurement group_id="O4" value="0.75" spread="0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Upper Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.886"/>
                    <measurement group_id="O2" value="0.90" spread="0.988"/>
                    <measurement group_id="O3" value="0.58" spread="0.874"/>
                    <measurement group_id="O4" value="0.81" spread="0.951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration (Trunk) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="0.619"/>
                    <measurement group_id="O2" value="2.74" spread="0.703"/>
                    <measurement group_id="O3" value="2.91" spread="0.772"/>
                    <measurement group_id="O4" value="2.93" spread="0.695"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Trunk) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" spread="0.913"/>
                    <measurement group_id="O2" value="2.33" spread="0.804"/>
                    <measurement group_id="O3" value="2.89" spread="0.689"/>
                    <measurement group_id="O4" value="2.90" spread="0.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Trunk) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.71" spread="1.109"/>
                    <measurement group_id="O2" value="1.95" spread="0.970"/>
                    <measurement group_id="O3" value="2.67" spread="0.919"/>
                    <measurement group_id="O4" value="2.71" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Trunk) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.142"/>
                    <measurement group_id="O2" value="1.51" spread="1.061"/>
                    <measurement group_id="O3" value="2.25" spread="1.080"/>
                    <measurement group_id="O4" value="2.54" spread="0.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Trunk) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="1.034"/>
                    <measurement group_id="O2" value="1.35" spread="1.115"/>
                    <measurement group_id="O3" value="2.00" spread="1.109"/>
                    <measurement group_id="O4" value="2.33" spread="0.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.961"/>
                    <measurement group_id="O2" value="1.15" spread="1.156"/>
                    <measurement group_id="O3" value="1.79" spread="1.298"/>
                    <measurement group_id="O4" value="2.18" spread="0.942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="0.976"/>
                    <measurement group_id="O2" value="1.01" spread="1.070"/>
                    <measurement group_id="O3" value="0.97" spread="0.972"/>
                    <measurement group_id="O4" value="1.13" spread="0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Trunk) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.846"/>
                    <measurement group_id="O2" value="0.96" spread="1.087"/>
                    <measurement group_id="O3" value="0.50" spread="0.980"/>
                    <measurement group_id="O4" value="0.70" spread="0.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Trunk) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.910"/>
                    <measurement group_id="O2" value="0.89" spread="1.037"/>
                    <measurement group_id="O3" value="0.38" spread="0.861"/>
                    <measurement group_id="O4" value="0.81" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Trunk) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.899"/>
                    <measurement group_id="O2" value="0.83" spread="1.012"/>
                    <measurement group_id="O3" value="0.50" spread="0.941"/>
                    <measurement group_id="O4" value="0.97" spread="1.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Induration (Lower Limbs) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="0.678"/>
                    <measurement group_id="O2" value="2.88" spread="0.708"/>
                    <measurement group_id="O3" value="3.02" spread="0.821"/>
                    <measurement group_id="O4" value="3.16" spread="0.680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Lower Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.39" spread="0.915"/>
                    <measurement group_id="O2" value="2.43" spread="0.888"/>
                    <measurement group_id="O3" value="2.93" spread="0.846"/>
                    <measurement group_id="O4" value="3.00" spread="0.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Lower Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1.102"/>
                    <measurement group_id="O2" value="2.09" spread="0.978"/>
                    <measurement group_id="O3" value="2.81" spread="0.932"/>
                    <measurement group_id="O4" value="2.93" spread="0.808"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Lower Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.138"/>
                    <measurement group_id="O2" value="1.61" spread="1.044"/>
                    <measurement group_id="O3" value="2.43" spread="1.035"/>
                    <measurement group_id="O4" value="2.67" spread="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Lower Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.878"/>
                    <measurement group_id="O2" value="1.36" spread="1.063"/>
                    <measurement group_id="O3" value="2.15" spread="0.975"/>
                    <measurement group_id="O4" value="2.49" spread="0.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" spread="0.798"/>
                    <measurement group_id="O2" value="1.24" spread="1.115"/>
                    <measurement group_id="O3" value="1.95" spread="1.138"/>
                    <measurement group_id="O4" value="2.46" spread="0.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="0.827"/>
                    <measurement group_id="O2" value="1.07" spread="1.027"/>
                    <measurement group_id="O3" value="1.05" spread="1.012"/>
                    <measurement group_id="O4" value="1.41" spread="0.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Lower Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.826"/>
                    <measurement group_id="O2" value="1.01" spread="1.088"/>
                    <measurement group_id="O3" value="0.58" spread="0.976"/>
                    <measurement group_id="O4" value="0.97" spread="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Lower Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.791"/>
                    <measurement group_id="O2" value="0.95" spread="1.011"/>
                    <measurement group_id="O3" value="0.68" spread="1.029"/>
                    <measurement group_id="O4" value="0.78" spread="0.898"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Lower Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.907"/>
                    <measurement group_id="O2" value="1.03" spread="1.069"/>
                    <measurement group_id="O3" value="0.67" spread="1.069"/>
                    <measurement group_id="O4" value="1.03" spread="1.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Head/Neck) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.40" spread="0.946"/>
                    <measurement group_id="O2" value="2.01" spread="1.011"/>
                    <measurement group_id="O3" value="2.25" spread="1.184"/>
                    <measurement group_id="O4" value="2.34" spread="0.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Head/Neck) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" spread="1.003"/>
                    <measurement group_id="O2" value="1.71" spread="1.004"/>
                    <measurement group_id="O3" value="2.11" spread="1.185"/>
                    <measurement group_id="O4" value="2.40" spread="0.939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Head/Neck) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="1.131"/>
                    <measurement group_id="O2" value="1.41" spread="1.068"/>
                    <measurement group_id="O3" value="1.84" spread="1.214"/>
                    <measurement group_id="O4" value="2.24" spread="0.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Head/Neck) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.986"/>
                    <measurement group_id="O2" value="1.02" spread="1.039"/>
                    <measurement group_id="O3" value="1.48" spread="1.109"/>
                    <measurement group_id="O4" value="2.03" spread="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Head/Neck) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.64" spread="0.887"/>
                    <measurement group_id="O2" value="0.85" spread="1.012"/>
                    <measurement group_id="O3" value="1.38" spread="1.030"/>
                    <measurement group_id="O4" value="1.82" spread="0.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.811"/>
                    <measurement group_id="O2" value="0.76" spread="1.025"/>
                    <measurement group_id="O3" value="1.21" spread="1.018"/>
                    <measurement group_id="O4" value="1.72" spread="0.999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" spread="0.664"/>
                    <measurement group_id="O2" value="0.67" spread="0.841"/>
                    <measurement group_id="O3" value="0.58" spread="0.758"/>
                    <measurement group_id="O4" value="0.85" spread="0.812"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Head/Neck) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.739"/>
                    <measurement group_id="O2" value="0.61" spread="0.809"/>
                    <measurement group_id="O3" value="0.29" spread="0.654"/>
                    <measurement group_id="O4" value="0.70" spread="0.878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Head/Neck) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.839"/>
                    <measurement group_id="O2" value="0.67" spread="0.894"/>
                    <measurement group_id="O3" value="0.35" spread="0.716"/>
                    <measurement group_id="O4" value="0.67" spread="0.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Head/Neck) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.897"/>
                    <measurement group_id="O2" value="0.63" spread="0.884"/>
                    <measurement group_id="O3" value="0.36" spread="0.723"/>
                    <measurement group_id="O4" value="0.72" spread="0.914"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Upper Limbs) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="0.779"/>
                    <measurement group_id="O2" value="2.60" spread="0.796"/>
                    <measurement group_id="O3" value="2.55" spread="0.848"/>
                    <measurement group_id="O4" value="2.82" spread="0.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Upper Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="0.922"/>
                    <measurement group_id="O2" value="2.19" spread="0.952"/>
                    <measurement group_id="O3" value="2.43" spread="0.900"/>
                    <measurement group_id="O4" value="2.62" spread="0.764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Upper Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.41" spread="1.106"/>
                    <measurement group_id="O2" value="1.77" spread="1.047"/>
                    <measurement group_id="O3" value="2.28" spread="1.031"/>
                    <measurement group_id="O4" value="2.52" spread="0.804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Upper Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.939"/>
                    <measurement group_id="O2" value="1.35" spread="1.018"/>
                    <measurement group_id="O3" value="1.93" spread="1.118"/>
                    <measurement group_id="O4" value="2.28" spread="0.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Upper Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.56" spread="0.841"/>
                    <measurement group_id="O2" value="1.14" spread="1.106"/>
                    <measurement group_id="O3" value="1.60" spread="1.033"/>
                    <measurement group_id="O4" value="2.23" spread="0.810"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.793"/>
                    <measurement group_id="O2" value="0.99" spread="1.070"/>
                    <measurement group_id="O3" value="1.50" spread="1.033"/>
                    <measurement group_id="O4" value="1.97" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" spread="0.807"/>
                    <measurement group_id="O2" value="0.86" spread="0.907"/>
                    <measurement group_id="O3" value="0.82" spread="0.834"/>
                    <measurement group_id="O4" value="1.21" spread="0.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Upper Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.708"/>
                    <measurement group_id="O2" value="0.93" spread="1.010"/>
                    <measurement group_id="O3" value="0.42" spread="0.642"/>
                    <measurement group_id="O4" value="0.81" spread="0.967"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Upper Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.801"/>
                    <measurement group_id="O2" value="0.96" spread="1.006"/>
                    <measurement group_id="O3" value="0.41" spread="0.686"/>
                    <measurement group_id="O4" value="0.83" spread="0.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Upper Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="0.763"/>
                    <measurement group_id="O2" value="0.95" spread="0.979"/>
                    <measurement group_id="O3" value="0.61" spread="0.871"/>
                    <measurement group_id="O4" value="0.92" spread="1.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Trunk) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="0.765"/>
                    <measurement group_id="O2" value="2.73" spread="0.784"/>
                    <measurement group_id="O3" value="2.77" spread="0.677"/>
                    <measurement group_id="O4" value="2.93" spread="0.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Trunk) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="0.928"/>
                    <measurement group_id="O2" value="2.27" spread="0.938"/>
                    <measurement group_id="O3" value="2.66" spread="0.745"/>
                    <measurement group_id="O4" value="2.76" spread="0.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Trunk) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.109"/>
                    <measurement group_id="O2" value="1.92" spread="0.997"/>
                    <measurement group_id="O3" value="2.49" spread="0.883"/>
                    <measurement group_id="O4" value="2.57" spread="0.770"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Trunk) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="1.057"/>
                    <measurement group_id="O2" value="1.48" spread="1.039"/>
                    <measurement group_id="O3" value="2.10" spread="1.008"/>
                    <measurement group_id="O4" value="2.38" spread="0.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Trunk) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="1.006"/>
                    <measurement group_id="O2" value="1.27" spread="1.132"/>
                    <measurement group_id="O3" value="1.73" spread="1.037"/>
                    <measurement group_id="O4" value="2.28" spread="0.857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.938"/>
                    <measurement group_id="O2" value="1.02" spread="1.097"/>
                    <measurement group_id="O3" value="1.58" spread="1.106"/>
                    <measurement group_id="O4" value="2.10" spread="0.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Trunk) n=84,84,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.871"/>
                    <measurement group_id="O2" value="0.96" spread="0.987"/>
                    <measurement group_id="O3" value="0.82" spread="0.955"/>
                    <measurement group_id="O4" value="1.13" spread="0.894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Trunk) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.754"/>
                    <measurement group_id="O2" value="0.92" spread="0.953"/>
                    <measurement group_id="O3" value="0.39" spread="0.823"/>
                    <measurement group_id="O4" value="0.68" spread="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Trunk) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.49" spread="0.882"/>
                    <measurement group_id="O2" value="0.91" spread="0.938"/>
                    <measurement group_id="O3" value="0.38" spread="0.861"/>
                    <measurement group_id="O4" value="0.78" spread="0.989"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Trunk) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="0.855"/>
                    <measurement group_id="O2" value="0.82" spread="0.818"/>
                    <measurement group_id="O3" value="0.53" spread="0.971"/>
                    <measurement group_id="O4" value="0.89" spread="0.887"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Scaling (Lower Limbs) n=90,88,44,44</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.94" spread="0.709"/>
                    <measurement group_id="O2" value="2.92" spread="0.776"/>
                    <measurement group_id="O3" value="2.84" spread="0.834"/>
                    <measurement group_id="O4" value="3.20" spread="0.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Lower Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.24" spread="1.017"/>
                    <measurement group_id="O2" value="2.40" spread="0.911"/>
                    <measurement group_id="O3" value="2.66" spread="0.888"/>
                    <measurement group_id="O4" value="2.98" spread="0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Lower Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.117"/>
                    <measurement group_id="O2" value="2.08" spread="0.997"/>
                    <measurement group_id="O3" value="2.49" spread="0.960"/>
                    <measurement group_id="O4" value="2.76" spread="0.906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Lower Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.15" spread="1.129"/>
                    <measurement group_id="O2" value="1.52" spread="1.093"/>
                    <measurement group_id="O3" value="2.20" spread="1.018"/>
                    <measurement group_id="O4" value="2.54" spread="0.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Lower Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.896"/>
                    <measurement group_id="O2" value="1.32" spread="1.120"/>
                    <measurement group_id="O3" value="2.03" spread="0.920"/>
                    <measurement group_id="O4" value="2.51" spread="0.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.783"/>
                    <measurement group_id="O2" value="1.20" spread="1.106"/>
                    <measurement group_id="O3" value="1.82" spread="1.062"/>
                    <measurement group_id="O4" value="2.38" spread="0.815"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.870"/>
                    <measurement group_id="O2" value="1.14" spread="1.020"/>
                    <measurement group_id="O3" value="0.95" spread="0.868"/>
                    <measurement group_id="O4" value="1.41" spread="0.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Lower Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.37" spread="0.760"/>
                    <measurement group_id="O2" value="1.08" spread="1.118"/>
                    <measurement group_id="O3" value="0.47" spread="0.797"/>
                    <measurement group_id="O4" value="1.03" spread="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Lower Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="0.976"/>
                    <measurement group_id="O2" value="1.06" spread="1.041"/>
                    <measurement group_id="O3" value="0.51" spread="0.731"/>
                    <measurement group_id="O4" value="0.83" spread="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Lower Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.61" spread="0.921"/>
                    <measurement group_id="O2" value="1.08" spread="1.042"/>
                    <measurement group_id="O3" value="0.67" spread="1.069"/>
                    <measurement group_id="O4" value="1.06" spread="1.120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PASI Component Scores Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PASI Component Scores Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and the &quot;percent of body surface area (BSA)&quot; affected. Basic characteristics of psoriatic lesions: erythema, induration, and scaling (PASI components) are scored separately for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]) according to a 5-point scale: 0 (no involvement); 1 (slight); 2 (moderate); 3 (marked); 4 (very marked). PASI component score range from 0 to 4, where higher scores indicate greater severity of psoriatic lesions.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: Erythema (Head/Neck) n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.676" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="-0.41" spread="0.757" lower_limit="22.09" upper_limit="41.55"/>
                    <measurement group_id="O3" value="-0.14" spread="0.594" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.10" spread="0.532" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Head/Neck) n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.94" spread="0.854" lower_limit="62.97" upper_limit="81.48"/>
                    <measurement group_id="O2" value="-0.74" spread="0.890" lower_limit="37.29" upper_limit="58.16"/>
                    <measurement group_id="O3" value="-0.26" spread="0.727" lower_limit="1.99" upper_limit="20.74"/>
                    <measurement group_id="O4" value="-0.17" spread="0.621" lower_limit="0.00" upper_limit="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Head/Neck) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="0.962" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="-1.05" spread="1.038" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="-0.20" spread="1.114" lower_limit="8.54" upper_limit="32.37"/>
                    <measurement group_id="O4" value="-0.38" spread="0.935" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Head/Neck) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="0.957" lower_limit="75.63" upper_limit="91.03"/>
                    <measurement group_id="O2" value="-1.24" spread="1.135" lower_limit="44.14" upper_limit="64.95"/>
                    <measurement group_id="O3" value="-0.38" spread="1.295" lower_limit="37.51" upper_limit="67.03"/>
                    <measurement group_id="O4" value="-0.46" spread="0.942" lower_limit="14.11" upper_limit="40.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="1.015" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="-1.43" spread="1.175" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="-0.66" spread="1.361" lower_limit="62.21" upper_limit="87.79"/>
                    <measurement group_id="O4" value="-0.62" spread="0.907" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="0.945" lower_limit="71.74" upper_limit="88.26"/>
                    <measurement group_id="O2" value="-1.43" spread="1.185" lower_limit="46.47" upper_limit="67.17"/>
                    <measurement group_id="O3" value="-1.37" spread="1.172" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="-1.36" spread="1.158" lower_limit="51.90" upper_limit="79.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Head/Neck) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="1.030" lower_limit="67.93" upper_limit="85.40"/>
                    <measurement group_id="O2" value="-1.51" spread="1.203" lower_limit="48.82" upper_limit="69.36"/>
                    <measurement group_id="O3" value="-1.68" spread="1.254" lower_limit="49.42" upper_limit="77.85"/>
                    <measurement group_id="O4" value="-1.59" spread="1.257" lower_limit="44.56" upper_limit="73.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Head/Neck) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="1.084"/>
                    <measurement group_id="O2" value="-1.51" spread="1.195"/>
                    <measurement group_id="O3" value="-1.68" spread="1.132"/>
                    <measurement group_id="O4" value="-1.81" spread="1.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Head/Neck) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.73" spread="1.079"/>
                    <measurement group_id="O2" value="-1.53" spread="1.181"/>
                    <measurement group_id="O3" value="-1.61" spread="1.225"/>
                    <measurement group_id="O4" value="-1.67" spread="1.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Upper Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" spread="0.698"/>
                    <measurement group_id="O2" value="-0.51" spread="0.609"/>
                    <measurement group_id="O3" value="0.02" spread="0.403"/>
                    <measurement group_id="O4" value="0.14" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Upper Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.858"/>
                    <measurement group_id="O2" value="-0.91" spread="0.839"/>
                    <measurement group_id="O3" value="-0.12" spread="0.697"/>
                    <measurement group_id="O4" value="-0.05" spread="0.582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Upper Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="0.984"/>
                    <measurement group_id="O2" value="-1.32" spread="0.977"/>
                    <measurement group_id="O3" value="-0.28" spread="0.784"/>
                    <measurement group_id="O4" value="-0.26" spread="0.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Upper Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="0.908"/>
                    <measurement group_id="O2" value="-1.61" spread="1.159"/>
                    <measurement group_id="O3" value="-0.50" spread="0.877"/>
                    <measurement group_id="O4" value="-0.41" spread="0.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="1.004"/>
                    <measurement group_id="O2" value="-1.81" spread="1.092"/>
                    <measurement group_id="O3" value="-0.92" spread="0.941"/>
                    <measurement group_id="O4" value="-0.44" spread="0.852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" spread="1.057"/>
                    <measurement group_id="O2" value="-1.87" spread="1.117"/>
                    <measurement group_id="O3" value="-1.66" spread="0.966"/>
                    <measurement group_id="O4" value="-1.38" spread="1.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Upper Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="0.957"/>
                    <measurement group_id="O2" value="-1.83" spread="1.257"/>
                    <measurement group_id="O3" value="-2.08" spread="1.148"/>
                    <measurement group_id="O4" value="-1.89" spread="0.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Upper Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.081"/>
                    <measurement group_id="O2" value="-1.89" spread="1.151"/>
                    <measurement group_id="O3" value="-2.05" spread="1.153"/>
                    <measurement group_id="O4" value="-1.94" spread="1.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Upper Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.14" spread="1.111"/>
                    <measurement group_id="O2" value="-1.85" spread="1.185"/>
                    <measurement group_id="O3" value="-1.94" spread="1.286"/>
                    <measurement group_id="O4" value="-1.83" spread="1.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Trunk) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="0.724"/>
                    <measurement group_id="O2" value="-0.41" spread="0.639"/>
                    <measurement group_id="O3" value="-0.02" spread="0.457"/>
                    <measurement group_id="O4" value="0.10" spread="0.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Trunk) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.05" spread="0.888"/>
                    <measurement group_id="O2" value="-0.76" spread="0.844"/>
                    <measurement group_id="O3" value="-0.14" spread="0.774"/>
                    <measurement group_id="O4" value="-0.12" spread="0.550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Trunk) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="1.041"/>
                    <measurement group_id="O2" value="-1.16" spread="0.969"/>
                    <measurement group_id="O3" value="-0.35" spread="0.949"/>
                    <measurement group_id="O4" value="-0.28" spread="0.560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Trunk) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="1.092"/>
                    <measurement group_id="O2" value="-1.36" spread="1.176"/>
                    <measurement group_id="O3" value="-0.65" spread="1.167"/>
                    <measurement group_id="O4" value="-0.38" spread="0.711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.21" spread="1.054"/>
                    <measurement group_id="O2" value="-1.61" spread="1.203"/>
                    <measurement group_id="O3" value="-0.97" spread="1.262"/>
                    <measurement group_id="O4" value="-0.28" spread="0.793"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.134"/>
                    <measurement group_id="O2" value="-1.70" spread="1.200"/>
                    <measurement group_id="O3" value="-1.76" spread="1.025"/>
                    <measurement group_id="O4" value="-1.62" spread="1.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Trunk) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="1.034"/>
                    <measurement group_id="O2" value="-1.80" spread="1.276"/>
                    <measurement group_id="O3" value="-2.32" spread="1.016"/>
                    <measurement group_id="O4" value="-2.22" spread="1.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Trunk) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="1.028"/>
                    <measurement group_id="O2" value="-1.86" spread="1.212"/>
                    <measurement group_id="O3" value="-2.43" spread="0.929"/>
                    <measurement group_id="O4" value="-2.22" spread="1.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Trunk) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="1.082"/>
                    <measurement group_id="O2" value="-1.82" spread="1.256"/>
                    <measurement group_id="O3" value="-2.22" spread="1.174"/>
                    <measurement group_id="O4" value="-1.97" spread="1.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Erythema (Lower Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" spread="0.587"/>
                    <measurement group_id="O2" value="-0.38" spread="0.722"/>
                    <measurement group_id="O3" value="0.00" spread="0.374"/>
                    <measurement group_id="O4" value="0.05" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Erythema (Lower Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.860"/>
                    <measurement group_id="O2" value="-0.75" spread="0.820"/>
                    <measurement group_id="O3" value="-0.12" spread="0.625"/>
                    <measurement group_id="O4" value="-0.12" spread="0.593"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Erythema (Lower Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="1.010"/>
                    <measurement group_id="O2" value="-1.19" spread="1.123"/>
                    <measurement group_id="O3" value="-0.33" spread="0.764"/>
                    <measurement group_id="O4" value="-0.26" spread="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Erythema (Lower Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.24" spread="0.965"/>
                    <measurement group_id="O2" value="-1.44" spread="1.183"/>
                    <measurement group_id="O3" value="-0.58" spread="0.958"/>
                    <measurement group_id="O4" value="-0.36" spread="0.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Erythema (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="1.014"/>
                    <measurement group_id="O2" value="-1.55" spread="1.255"/>
                    <measurement group_id="O3" value="-0.89" spread="1.085"/>
                    <measurement group_id="O4" value="-0.41" spread="0.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Erythema (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.49" spread="1.000"/>
                    <measurement group_id="O2" value="-1.73" spread="1.274"/>
                    <measurement group_id="O3" value="-1.87" spread="0.991"/>
                    <measurement group_id="O4" value="-1.41" spread="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Erythema (Lower Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.54" spread="1.028"/>
                    <measurement group_id="O2" value="-1.86" spread="1.372"/>
                    <measurement group_id="O3" value="-2.37" spread="1.025"/>
                    <measurement group_id="O4" value="-2.05" spread="1.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Erythema (Lower Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" spread="1.062"/>
                    <measurement group_id="O2" value="-1.86" spread="1.243"/>
                    <measurement group_id="O3" value="-2.32" spread="1.082"/>
                    <measurement group_id="O4" value="-2.33" spread="1.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Erythema (Lower Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="1.077"/>
                    <measurement group_id="O2" value="-1.74" spread="1.400"/>
                    <measurement group_id="O3" value="-2.25" spread="1.251"/>
                    <measurement group_id="O4" value="-2.19" spread="1.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Head/Neck) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.59" spread="0.705"/>
                    <measurement group_id="O2" value="-0.27" spread="0.602"/>
                    <measurement group_id="O3" value="-0.07" spread="0.398"/>
                    <measurement group_id="O4" value="-0.02" spread="0.468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Head/Neck) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.07" spread="0.974"/>
                    <measurement group_id="O2" value="-0.59" spread="0.892"/>
                    <measurement group_id="O3" value="-0.30" spread="0.708"/>
                    <measurement group_id="O4" value="-0.12" spread="0.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Head/Neck) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.080"/>
                    <measurement group_id="O2" value="-0.86" spread="0.937"/>
                    <measurement group_id="O3" value="-0.50" spread="1.086"/>
                    <measurement group_id="O4" value="-0.33" spread="0.927"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Head/Neck) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="1.032"/>
                    <measurement group_id="O2" value="-1.08" spread="1.031"/>
                    <measurement group_id="O3" value="-0.65" spread="1.075"/>
                    <measurement group_id="O4" value="-0.54" spread="0.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="1.106"/>
                    <measurement group_id="O2" value="-1.24" spread="1.060"/>
                    <measurement group_id="O3" value="-0.76" spread="1.240"/>
                    <measurement group_id="O4" value="-0.69" spread="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.058"/>
                    <measurement group_id="O2" value="-1.30" spread="1.084"/>
                    <measurement group_id="O3" value="-1.47" spread="1.133"/>
                    <measurement group_id="O4" value="-1.36" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Head/Neck) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="1.121"/>
                    <measurement group_id="O2" value="-1.41" spread="1.094"/>
                    <measurement group_id="O3" value="-1.74" spread="1.155"/>
                    <measurement group_id="O4" value="-1.65" spread="1.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Head/Neck) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.124"/>
                    <measurement group_id="O2" value="-1.37" spread="1.066"/>
                    <measurement group_id="O3" value="-1.68" spread="1.056"/>
                    <measurement group_id="O4" value="-1.78" spread="1.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Head/Neck) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68" spread="1.178"/>
                    <measurement group_id="O2" value="-1.36" spread="1.139"/>
                    <measurement group_id="O3" value="-1.58" spread="1.228"/>
                    <measurement group_id="O4" value="-1.69" spread="1.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Upper Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.766"/>
                    <measurement group_id="O2" value="-0.42" spread="0.727"/>
                    <measurement group_id="O3" value="-0.05" spread="0.526"/>
                    <measurement group_id="O4" value="-0.07" spread="0.407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Upper Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.17" spread="1.048"/>
                    <measurement group_id="O2" value="-0.77" spread="0.867"/>
                    <measurement group_id="O3" value="-0.21" spread="0.833"/>
                    <measurement group_id="O4" value="-0.19" spread="0.707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Upper Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.69" spread="1.024"/>
                    <measurement group_id="O2" value="-1.19" spread="1.092"/>
                    <measurement group_id="O3" value="-0.55" spread="1.011"/>
                    <measurement group_id="O4" value="-0.41" spread="0.751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Upper Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.17" spread="0.862"/>
                    <measurement group_id="O2" value="-1.47" spread="1.231"/>
                    <measurement group_id="O3" value="-0.80" spread="1.091"/>
                    <measurement group_id="O4" value="-0.54" spread="0.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="0.867"/>
                    <measurement group_id="O2" value="-1.52" spread="1.217"/>
                    <measurement group_id="O3" value="-1.05" spread="1.293"/>
                    <measurement group_id="O4" value="-0.69" spread="0.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="1.012"/>
                    <measurement group_id="O2" value="-1.67" spread="1.186"/>
                    <measurement group_id="O3" value="-1.71" spread="1.250"/>
                    <measurement group_id="O4" value="-1.59" spread="1.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Upper Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="1.018"/>
                    <measurement group_id="O2" value="-1.61" spread="1.296"/>
                    <measurement group_id="O3" value="-2.03" spread="1.150"/>
                    <measurement group_id="O4" value="-1.97" spread="1.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Upper Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="1.067"/>
                    <measurement group_id="O2" value="-1.65" spread="1.266"/>
                    <measurement group_id="O3" value="-2.11" spread="1.100"/>
                    <measurement group_id="O4" value="-1.97" spread="1.108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Upper Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.20" spread="1.107"/>
                    <measurement group_id="O2" value="-1.69" spread="1.282"/>
                    <measurement group_id="O3" value="-2.03" spread="1.183"/>
                    <measurement group_id="O4" value="-1.92" spread="1.204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Trunk) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.728"/>
                    <measurement group_id="O2" value="-0.43" spread="0.660"/>
                    <measurement group_id="O3" value="-0.02" spread="0.457"/>
                    <measurement group_id="O4" value="-0.05" spread="0.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Trunk) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.20" spread="1.044"/>
                    <measurement group_id="O2" value="-0.78" spread="0.850"/>
                    <measurement group_id="O3" value="-0.23" spread="0.812"/>
                    <measurement group_id="O4" value="-0.24" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Trunk) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="1.084"/>
                    <measurement group_id="O2" value="-1.23" spread="1.003"/>
                    <measurement group_id="O3" value="-0.68" spread="1.071"/>
                    <measurement group_id="O4" value="-0.38" spread="0.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Trunk) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="1.035"/>
                    <measurement group_id="O2" value="-1.39" spread="1.129"/>
                    <measurement group_id="O3" value="-0.90" spread="1.194"/>
                    <measurement group_id="O4" value="-0.59" spread="0.637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="0.965"/>
                    <measurement group_id="O2" value="-1.57" spread="1.154"/>
                    <measurement group_id="O3" value="-1.13" spread="1.398"/>
                    <measurement group_id="O4" value="-0.74" spread="0.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" spread="0.984"/>
                    <measurement group_id="O2" value="-1.71" spread="1.071"/>
                    <measurement group_id="O3" value="-1.95" spread="1.138"/>
                    <measurement group_id="O4" value="-1.79" spread="1.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Trunk) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="0.938"/>
                    <measurement group_id="O2" value="-1.76" spread="1.122"/>
                    <measurement group_id="O3" value="-2.42" spread="1.222"/>
                    <measurement group_id="O4" value="-2.22" spread="1.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Trunk) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="1.058"/>
                    <measurement group_id="O2" value="-1.84" spread="1.145"/>
                    <measurement group_id="O3" value="-2.57" spread="1.068"/>
                    <measurement group_id="O4" value="-2.08" spread="1.360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Trunk) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="1.070"/>
                    <measurement group_id="O2" value="-1.90" spread="1.180"/>
                    <measurement group_id="O3" value="-2.47" spread="1.207"/>
                    <measurement group_id="O4" value="-1.92" spread="1.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Induration (Lower Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.803"/>
                    <measurement group_id="O2" value="-0.43" spread="0.660"/>
                    <measurement group_id="O3" value="-0.09" spread="0.421"/>
                    <measurement group_id="O4" value="-0.14" spread="0.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Induration (Lower Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="0.993"/>
                    <measurement group_id="O2" value="-0.78" spread="0.809"/>
                    <measurement group_id="O3" value="-0.21" spread="0.773"/>
                    <measurement group_id="O4" value="-0.21" spread="0.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Induration (Lower Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.82" spread="1.002"/>
                    <measurement group_id="O2" value="-1.26" spread="0.977"/>
                    <measurement group_id="O3" value="-0.60" spread="0.955"/>
                    <measurement group_id="O4" value="-0.49" spread="0.683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Induration (Lower Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="0.845"/>
                    <measurement group_id="O2" value="-1.51" spread="1.093"/>
                    <measurement group_id="O3" value="-0.85" spread="0.975"/>
                    <measurement group_id="O4" value="-0.67" spread="0.772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Induration (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="0.814"/>
                    <measurement group_id="O2" value="-1.63" spread="1.159"/>
                    <measurement group_id="O3" value="-1.08" spread="1.148"/>
                    <measurement group_id="O4" value="-0.69" spread="0.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Induration (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.61" spread="0.865"/>
                    <measurement group_id="O2" value="-1.80" spread="1.039"/>
                    <measurement group_id="O3" value="-1.97" spread="1.026"/>
                    <measurement group_id="O4" value="-1.74" spread="0.818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Induration (Lower Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" spread="0.957"/>
                    <measurement group_id="O2" value="-1.86" spread="1.106"/>
                    <measurement group_id="O3" value="-2.45" spread="1.083"/>
                    <measurement group_id="O4" value="-2.14" spread="1.058"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Induration (Lower Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="0.974"/>
                    <measurement group_id="O2" value="-1.93" spread="1.022"/>
                    <measurement group_id="O3" value="-2.35" spread="1.033"/>
                    <measurement group_id="O4" value="-2.31" spread="1.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Induration (Lower Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.43" spread="1.041"/>
                    <measurement group_id="O2" value="-1.85" spread="1.140"/>
                    <measurement group_id="O3" value="-2.39" spread="1.178"/>
                    <measurement group_id="O4" value="-2.06" spread="1.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Head/Neck) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.802"/>
                    <measurement group_id="O2" value="-0.28" spread="0.587"/>
                    <measurement group_id="O3" value="-0.14" spread="0.594"/>
                    <measurement group_id="O4" value="0.05" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Head/Neck) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.16" spread="1.077"/>
                    <measurement group_id="O2" value="-0.60" spread="0.766"/>
                    <measurement group_id="O3" value="-0.40" spread="0.955"/>
                    <measurement group_id="O4" value="-0.12" spread="0.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Head/Neck) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="1.157"/>
                    <measurement group_id="O2" value="-0.99" spread="1.000"/>
                    <measurement group_id="O3" value="-0.75" spread="1.296"/>
                    <measurement group_id="O4" value="-0.38" spread="0.963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Head/Neck) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.137"/>
                    <measurement group_id="O2" value="-1.16" spread="1.103"/>
                    <measurement group_id="O3" value="-0.83" spread="1.338"/>
                    <measurement group_id="O4" value="-0.59" spread="0.993"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.160"/>
                    <measurement group_id="O2" value="-1.31" spread="1.151"/>
                    <measurement group_id="O3" value="-0.97" spread="1.404"/>
                    <measurement group_id="O4" value="-0.69" spread="0.977"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Head/Neck) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.98" spread="1.075"/>
                    <measurement group_id="O2" value="-1.40" spread="1.110"/>
                    <measurement group_id="O3" value="-1.61" spread="1.366"/>
                    <measurement group_id="O4" value="-1.56" spread="1.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Head/Neck) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.92" spread="1.073"/>
                    <measurement group_id="O2" value="-1.47" spread="1.162"/>
                    <measurement group_id="O3" value="-1.89" spread="1.290"/>
                    <measurement group_id="O4" value="-1.70" spread="1.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Head/Neck) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.88" spread="1.198"/>
                    <measurement group_id="O2" value="-1.41" spread="1.138"/>
                    <measurement group_id="O3" value="-1.78" spread="1.250"/>
                    <measurement group_id="O4" value="-1.78" spread="1.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Head/Neck) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.192"/>
                    <measurement group_id="O2" value="-1.45" spread="1.202"/>
                    <measurement group_id="O3" value="-1.78" spread="1.456"/>
                    <measurement group_id="O4" value="-1.72" spread="1.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Upper Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.72" spread="0.843"/>
                    <measurement group_id="O2" value="-0.41" spread="0.602"/>
                    <measurement group_id="O3" value="-0.11" spread="0.579"/>
                    <measurement group_id="O4" value="-0.19" spread="0.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Upper Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.154"/>
                    <measurement group_id="O2" value="-0.83" spread="0.847"/>
                    <measurement group_id="O3" value="-0.26" spread="0.848"/>
                    <measurement group_id="O4" value="-0.29" spread="0.742"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Upper Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="1.078"/>
                    <measurement group_id="O2" value="-1.25" spread="0.950"/>
                    <measurement group_id="O3" value="-0.63" spread="1.030"/>
                    <measurement group_id="O4" value="-0.56" spread="0.940"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Upper Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="0.894"/>
                    <measurement group_id="O2" value="-1.47" spread="1.114"/>
                    <measurement group_id="O3" value="-0.93" spread="1.023"/>
                    <measurement group_id="O4" value="-0.62" spread="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="0.998"/>
                    <measurement group_id="O2" value="-1.62" spread="1.040"/>
                    <measurement group_id="O3" value="-1.00" spread="1.115"/>
                    <measurement group_id="O4" value="-0.87" spread="1.105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Upper Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" spread="1.047"/>
                    <measurement group_id="O2" value="-1.75" spread="1.005"/>
                    <measurement group_id="O3" value="-1.68" spread="1.093"/>
                    <measurement group_id="O4" value="-1.64" spread="1.112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Upper Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="1.009"/>
                    <measurement group_id="O2" value="-1.67" spread="1.025"/>
                    <measurement group_id="O3" value="-2.08" spread="0.997"/>
                    <measurement group_id="O4" value="-2.03" spread="1.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Upper Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.32" spread="1.127"/>
                    <measurement group_id="O2" value="-1.65" spread="1.153"/>
                    <measurement group_id="O3" value="-2.08" spread="1.064"/>
                    <measurement group_id="O4" value="-2.00" spread="1.195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Upper Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.25" spread="1.175"/>
                    <measurement group_id="O2" value="-1.68" spread="1.201"/>
                    <measurement group_id="O3" value="-1.89" spread="1.282"/>
                    <measurement group_id="O4" value="-1.92" spread="1.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Trunk) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.810"/>
                    <measurement group_id="O2" value="-0.49" spread="0.682"/>
                    <measurement group_id="O3" value="-0.11" spread="0.655"/>
                    <measurement group_id="O4" value="-0.17" spread="0.490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Trunk) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.104"/>
                    <measurement group_id="O2" value="-0.81" spread="0.842"/>
                    <measurement group_id="O3" value="-0.28" spread="0.934"/>
                    <measurement group_id="O4" value="-0.36" spread="0.692"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Trunk) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.79" spread="1.124"/>
                    <measurement group_id="O2" value="-1.25" spread="0.997"/>
                    <measurement group_id="O3" value="-0.70" spread="1.018"/>
                    <measurement group_id="O4" value="-0.54" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Trunk) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.06" spread="1.045"/>
                    <measurement group_id="O2" value="-1.45" spread="1.174"/>
                    <measurement group_id="O3" value="-1.05" spread="1.154"/>
                    <measurement group_id="O4" value="-0.64" spread="0.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.23" spread="1.090"/>
                    <measurement group_id="O2" value="-1.71" spread="1.136"/>
                    <measurement group_id="O3" value="-1.21" spread="1.255"/>
                    <measurement group_id="O4" value="-0.82" spread="0.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Trunk) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.26" spread="1.088"/>
                    <measurement group_id="O2" value="-1.77" spread="1.090"/>
                    <measurement group_id="O3" value="-1.97" spread="1.219"/>
                    <measurement group_id="O4" value="-1.79" spread="1.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Trunk) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.28" spread="0.992"/>
                    <measurement group_id="O2" value="-1.82" spread="1.049"/>
                    <measurement group_id="O3" value="-2.39" spread="1.054"/>
                    <measurement group_id="O4" value="-2.22" spread="1.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Trunk) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="1.173"/>
                    <measurement group_id="O2" value="-1.83" spread="1.160"/>
                    <measurement group_id="O3" value="-2.43" spread="1.042"/>
                    <measurement group_id="O4" value="-2.11" spread="1.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Trunk) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="1.188"/>
                    <measurement group_id="O2" value="-1.94" spread="1.049"/>
                    <measurement group_id="O3" value="-2.31" spread="1.215"/>
                    <measurement group_id="O4" value="-2.00" spread="1.352"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: Scaling (Lower Limbs) n=88,86,44,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.846"/>
                    <measurement group_id="O2" value="-0.51" spread="0.778"/>
                    <measurement group_id="O3" value="-0.18" spread="0.657"/>
                    <measurement group_id="O4" value="-0.21" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: Scaling (Lower Limbs) n=87,88,43,42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" spread="1.016"/>
                    <measurement group_id="O2" value="-0.84" spread="0.933"/>
                    <measurement group_id="O3" value="-0.35" spread="0.997"/>
                    <measurement group_id="O4" value="-0.43" spread="0.668"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: Scaling (Lower Limbs) n=85,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="1.044"/>
                    <measurement group_id="O2" value="-1.40" spread="1.078"/>
                    <measurement group_id="O3" value="-0.63" spread="1.125"/>
                    <measurement group_id="O4" value="-0.69" spread="0.863"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: Scaling (Lower Limbs) n=84,88,40,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" spread="0.915"/>
                    <measurement group_id="O2" value="-1.60" spread="1.160"/>
                    <measurement group_id="O3" value="-0.75" spread="1.080"/>
                    <measurement group_id="O4" value="-0.72" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: Scaling (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="0.912"/>
                    <measurement group_id="O2" value="-1.74" spread="1.173"/>
                    <measurement group_id="O3" value="-0.95" spread="1.293"/>
                    <measurement group_id="O4" value="-0.85" spread="1.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Scaling (Lower Limbs) n=84,84,38,39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="0.963"/>
                    <measurement group_id="O2" value="-1.80" spread="1.138"/>
                    <measurement group_id="O3" value="-1.82" spread="1.136"/>
                    <measurement group_id="O4" value="-1.82" spread="1.023"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32: Scaling (Lower Limbs) n=83,83,38,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.58" spread="0.964"/>
                    <measurement group_id="O2" value="-1.86" spread="1.128"/>
                    <measurement group_id="O3" value="-2.29" spread="1.160"/>
                    <measurement group_id="O4" value="-2.16" spread="1.236"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40: Scaling (Lower Limbs) n=81,81,37,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.40" spread="1.190"/>
                    <measurement group_id="O2" value="-1.89" spread="1.118"/>
                    <measurement group_id="O3" value="-2.22" spread="1.004"/>
                    <measurement group_id="O4" value="-2.33" spread="1.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Scaling (Lower Limbs) n=80,78,36,36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.33" spread="1.111"/>
                    <measurement group_id="O2" value="-1.88" spread="1.151"/>
                    <measurement group_id="O3" value="-2.08" spread="1.360"/>
                    <measurement group_id="O4" value="-2.11" spread="1.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in PASI Scores Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in PASI Scores Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.93" spread="2.399" lower_limit="15.57" upper_limit="33.32"/>
                    <measurement group_id="O2" value="-16.28" spread="2.409" lower_limit="0.19" upper_limit="8.90"/>
                    <measurement group_id="O3" value="1.37" spread="3.392" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="-0.35" spread="3.473" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.24" spread="3.135"/>
                    <measurement group_id="O2" value="-32.47" spread="3.127"/>
                    <measurement group_id="O3" value="-1.98" spread="4.444"/>
                    <measurement group_id="O4" value="-7.31" spread="4.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-66.96" spread="3.769"/>
                    <measurement group_id="O2" value="-51.24" spread="3.739"/>
                    <measurement group_id="O3" value="-13.17" spread="5.384"/>
                    <measurement group_id="O4" value="-16.18" spread="5.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.64" spread="3.631"/>
                    <measurement group_id="O2" value="-59.73" spread="3.585"/>
                    <measurement group_id="O3" value="-25.13" spread="5.205"/>
                    <measurement group_id="O4" value="-20.40" spread="5.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.35" spread="3.912"/>
                    <measurement group_id="O2" value="-66.69" spread="3.874"/>
                    <measurement group_id="O3" value="-32.79" spread="5.651"/>
                    <measurement group_id="O4" value="-21.63" spread="5.721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.89" spread="3.024"/>
                    <measurement group_id="O2" value="-71.93" spread="3.002"/>
                    <measurement group_id="O3" value="-69.85" spread="4.399"/>
                    <measurement group_id="O4" value="-60.85" spread="4.423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.47" spread="2.444"/>
                    <measurement group_id="O2" value="-76.06" spread="2.437"/>
                    <measurement group_id="O3" value="-86.63" spread="3.584"/>
                    <measurement group_id="O4" value="-81.43" spread="3.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.18" spread="2.264"/>
                    <measurement group_id="O2" value="-77.29" spread="2.258"/>
                    <measurement group_id="O3" value="-87.73" spread="3.332"/>
                    <measurement group_id="O4" value="-83.64" spread="3.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-86.05" spread="2.763"/>
                    <measurement group_id="O2" value="-75.55" spread="2.764"/>
                    <measurement group_id="O3" value="-84.65" spread="4.066"/>
                    <measurement group_id="O4" value="-79.27" spread="4.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual BSA Over Time Through Week 52</title>
        <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual BSA Over Time Through Week 52</title>
          <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>percent BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.36" spread="18.035" lower_limit="15.57" upper_limit="33.32"/>
                    <measurement group_id="O2" value="37.41" spread="19.614" lower_limit="0.19" upper_limit="8.90"/>
                    <measurement group_id="O3" value="35.29" spread="18.294" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="36.25" spread="16.018" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=88,86,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.95" spread="17.537"/>
                    <measurement group_id="O2" value="36.56" spread="19.363"/>
                    <measurement group_id="O3" value="36.84" spread="18.808"/>
                    <measurement group_id="O4" value="36.38" spread="16.592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.82" spread="18.599"/>
                    <measurement group_id="O2" value="32.75" spread="18.314"/>
                    <measurement group_id="O3" value="38.32" spread="19.355"/>
                    <measurement group_id="O4" value="36.30" spread="16.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.62" spread="18.411"/>
                    <measurement group_id="O2" value="24.38" spread="19.583"/>
                    <measurement group_id="O3" value="36.75" spread="19.817"/>
                    <measurement group_id="O4" value="34.99" spread="16.182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.59" spread="15.486"/>
                    <measurement group_id="O2" value="20.45" spread="20.462"/>
                    <measurement group_id="O3" value="33.15" spread="20.483"/>
                    <measurement group_id="O4" value="34.06" spread="17.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.57" spread="13.395"/>
                    <measurement group_id="O2" value="16.52" spread="18.899"/>
                    <measurement group_id="O3" value="28.57" spread="21.645"/>
                    <measurement group_id="O4" value="34.54" spread="18.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.05" spread="10.041"/>
                    <measurement group_id="O2" value="13.69" spread="16.976"/>
                    <measurement group_id="O3" value="15.50" spread="16.522"/>
                    <measurement group_id="O4" value="24.83" spread="19.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" spread="5.894"/>
                    <measurement group_id="O2" value="11.47" spread="16.304"/>
                    <measurement group_id="O3" value="6.95" spread="10.262"/>
                    <measurement group_id="O4" value="9.03" spread="11.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="5.412"/>
                    <measurement group_id="O2" value="10.32" spread="13.077"/>
                    <measurement group_id="O3" value="5.88" spread="8.351"/>
                    <measurement group_id="O4" value="6.35" spread="9.462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="7.908"/>
                    <measurement group_id="O2" value="10.94" spread="15.255"/>
                    <measurement group_id="O3" value="5.00" spread="7.686"/>
                    <measurement group_id="O4" value="7.87" spread="9.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in BSA Over Time Through Week 52</title>
        <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
        <time_frame>Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in BSA Over Time Through Week 52</title>
          <description>Assessment of BSA with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (fully extended palm, fingers and thumb together) represented approximately 1% of the total BSA. Body regions are assigned specific number of handprints with percentage [Head and neck = 10% (10 handprints), upper extremities = 20% (20 handprints), Trunk (including axillae and groin) = 30% (30 handprints), lower extremities (including buttocks) = 40% (40 handprints)]. The number of handprints of psoriatic skin in a body region was used to determine the extent (%) to which a body region was involved with psoriasis. The total BSA affected was the summation of individual regions affected.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=88,86,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.58" spread="2.083"/>
                    <measurement group_id="O2" value="-2.53" spread="2.093"/>
                    <measurement group_id="O3" value="4.79" spread="2.947"/>
                    <measurement group_id="O4" value="2.14" spread="3.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.90" spread="3.202"/>
                    <measurement group_id="O2" value="-10.98" spread="3.193"/>
                    <measurement group_id="O3" value="10.29" spread="4.541"/>
                    <measurement group_id="O4" value="2.28" spread="4.622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-46.98" spread="4.909"/>
                    <measurement group_id="O2" value="-33.22" spread="4.870"/>
                    <measurement group_id="O3" value="8.73" spread="7.017"/>
                    <measurement group_id="O4" value="-0.42" spread="7.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-65.97" spread="5.536"/>
                    <measurement group_id="O2" value="-44.44" spread="5.471"/>
                    <measurement group_id="O3" value="0.41" spread="7.928"/>
                    <measurement group_id="O4" value="0.48" spread="8.086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.80" spread="5.903"/>
                    <measurement group_id="O2" value="-54.41" spread="5.839"/>
                    <measurement group_id="O3" value="-8.85" spread="8.511"/>
                    <measurement group_id="O4" value="4.13" spread="8.632"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-82.65" spread="4.459"/>
                    <measurement group_id="O2" value="-62.35" spread="4.419"/>
                    <measurement group_id="O3" value="-49.35" spread="6.495"/>
                    <measurement group_id="O4" value="-28.86" spread="6.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-87.55" spread="3.531"/>
                    <measurement group_id="O2" value="-70.55" spread="3.521"/>
                    <measurement group_id="O3" value="-74.83" spread="5.186"/>
                    <measurement group_id="O4" value="-73.95" spread="5.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-90.00" spread="3.213"/>
                    <measurement group_id="O2" value="-73.00" spread="3.207"/>
                    <measurement group_id="O3" value="-79.48" spread="4.743"/>
                    <measurement group_id="O4" value="-79.91" spread="4.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.16" spread="3.867"/>
                    <measurement group_id="O2" value="-72.28" spread="3.868"/>
                    <measurement group_id="O3" value="-81.70" spread="5.681"/>
                    <measurement group_id="O4" value="-74.02" spread="5.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PASI50 Response Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI50 response is reported.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PASI50 Response Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 50 response was defined as at least 50% reduction in PASI relative to Baseline. Percentage of participants with PASI50 response is reported.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.11" lower_limit="12.68" upper_limit="29.54"/>
                    <measurement group_id="O2" value="5.68" lower_limit="0.85" upper_limit="10.52"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.89" lower_limit="38.56" upper_limit="59.22"/>
                    <measurement group_id="O2" value="27.27" lower_limit="17.97" upper_limit="36.58"/>
                    <measurement group_id="O3" value="4.55" lower_limit="0.00" upper_limit="10.70"/>
                    <measurement group_id="O4" value="4.55" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.44" lower_limit="65.43" upper_limit="83.46"/>
                    <measurement group_id="O2" value="55.68" lower_limit="45.30" upper_limit="66.06"/>
                    <measurement group_id="O3" value="13.64" lower_limit="3.50" upper_limit="23.78"/>
                    <measurement group_id="O4" value="4.55" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.11" lower_limit="73.02" upper_limit="89.20"/>
                    <measurement group_id="O2" value="64.77" lower_limit="54.79" upper_limit="74.75"/>
                    <measurement group_id="O3" value="27.27" lower_limit="14.11" upper_limit="40.43"/>
                    <measurement group_id="O4" value="9.09" lower_limit="0.60" upper_limit="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.67" lower_limit="79.64" upper_limit="93.69"/>
                    <measurement group_id="O2" value="71.59" lower_limit="62.17" upper_limit="81.01"/>
                    <measurement group_id="O3" value="40.91" lower_limit="26.38" upper_limit="55.44"/>
                    <measurement group_id="O4" value="18.18" lower_limit="6.79" upper_limit="29.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.56" lower_limit="78.29" upper_limit="92.82"/>
                    <measurement group_id="O2" value="72.73" lower_limit="63.42" upper_limit="82.03"/>
                    <measurement group_id="O3" value="68.18" lower_limit="54.42" upper_limit="81.94"/>
                    <measurement group_id="O4" value="63.64" lower_limit="49.42" upper_limit="77.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.89" lower_limit="82.40" upper_limit="95.38"/>
                    <measurement group_id="O2" value="78.41" lower_limit="69.81" upper_limit="87.01"/>
                    <measurement group_id="O3" value="79.55" lower_limit="67.63" upper_limit="91.46"/>
                    <measurement group_id="O4" value="75.00" lower_limit="62.21" upper_limit="87.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.78" lower_limit="81.01" upper_limit="94.54"/>
                    <measurement group_id="O2" value="80.68" lower_limit="72.43" upper_limit="88.93"/>
                    <measurement group_id="O3" value="79.55" lower_limit="67.63" upper_limit="91.46"/>
                    <measurement group_id="O4" value="72.73" lower_limit="59.57" upper_limit="85.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.33" lower_limit="75.63" upper_limit="91.03"/>
                    <measurement group_id="O2" value="73.86" lower_limit="64.68" upper_limit="83.04"/>
                    <measurement group_id="O3" value="77.27" lower_limit="64.89" upper_limit="89.66"/>
                    <measurement group_id="O4" value="75.00" lower_limit="62.21" upper_limit="87.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PASI90 Response Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI90 response up to Week 52 is reported.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PASI90 Response Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both, &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI 90 response was defined as at least 90% reduction in PASI relative to Baseline. Percentage of participants with PASI90 response up to Week 52 is reported.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" lower_limit="2.24" upper_limit="13.31"/>
                    <measurement group_id="O2" value="2.27" lower_limit="0.00" upper_limit="5.39"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.78" lower_limit="18.52" upper_limit="37.03"/>
                    <measurement group_id="O2" value="13.64" lower_limit="6.47" upper_limit="20.81"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.11" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="29.55" lower_limit="20.01" upper_limit="39.08"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.00" lower_limit="49.88" upper_limit="70.12"/>
                    <measurement group_id="O2" value="35.23" lower_limit="25.25" upper_limit="45.21"/>
                    <measurement group_id="O3" value="6.82" lower_limit="0.00" upper_limit="14.27"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.11" lower_limit="61.75" upper_limit="80.48"/>
                    <measurement group_id="O2" value="35.23" lower_limit="25.25" upper_limit="45.21"/>
                    <measurement group_id="O3" value="25.00" lower_limit="12.21" upper_limit="37.79"/>
                    <measurement group_id="O4" value="9.09" lower_limit="0.60" upper_limit="17.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.56" lower_limit="55.74" upper_limit="75.37"/>
                    <measurement group_id="O2" value="42.05" lower_limit="31.73" upper_limit="52.36"/>
                    <measurement group_id="O3" value="56.82" lower_limit="42.18" upper_limit="71.45"/>
                    <measurement group_id="O4" value="40.91" lower_limit="26.38" upper_limit="55.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.67" lower_limit="56.93" upper_limit="76.41"/>
                    <measurement group_id="O2" value="35.23" lower_limit="25.25" upper_limit="45.21"/>
                    <measurement group_id="O3" value="56.82" lower_limit="42.18" upper_limit="71.45"/>
                    <measurement group_id="O4" value="45.45" lower_limit="30.74" upper_limit="60.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" lower_limit="46.43" upper_limit="66.90"/>
                    <measurement group_id="O2" value="38.64" lower_limit="28.46" upper_limit="48.81"/>
                    <measurement group_id="O3" value="56.82" lower_limit="42.18" upper_limit="71.45"/>
                    <measurement group_id="O4" value="36.36" lower_limit="22.15" upper_limit="50.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With PASI125 Over Time Through Week 52</title>
        <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With PASI125 Over Time Through Week 52</title>
          <description>The PASI quantifies the severity of a participant's psoriasis based on both &quot;lesion severity&quot; and &quot;percent of BSA&quot; affected. PASI is a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk [including axillae and groin], and lower limbs [including buttocks]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. Percentage of participants with PASI score of at least 125% of baseline PASI score are reported.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.27" lower_limit="0.00" upper_limit="5.39"/>
                    <measurement group_id="O2" value="1.16" lower_limit="0.00" upper_limit="3.43"/>
                    <measurement group_id="O3" value="4.55" lower_limit="0.00" upper_limit="10.70"/>
                    <measurement group_id="O4" value="4.76" lower_limit="0.00" upper_limit="11.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" lower_limit="0.00" upper_limit="5.45"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.00" upper_limit="3.35"/>
                    <measurement group_id="O3" value="13.95" lower_limit="3.60" upper_limit="24.31"/>
                    <measurement group_id="O4" value="2.38" lower_limit="0.00" upper_limit="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="0.00" upper_limit="5.58"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.00" upper_limit="3.35"/>
                    <measurement group_id="O3" value="17.50" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O4" value="2.56" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="1.14" lower_limit="0.00" upper_limit="3.35"/>
                    <measurement group_id="O3" value="7.50" lower_limit="0.00" upper_limit="15.66"/>
                    <measurement group_id="O4" value="5.13" lower_limit="0.00" upper_limit="12.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="2.38" lower_limit="0.00" upper_limit="5.64"/>
                    <measurement group_id="O3" value="10.53" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O4" value="7.69" lower_limit="0.00" upper_limit="16.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="2.56" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,83,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.00" upper_limit="3.68"/>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
        <time_frame>Baseline and Weeks 8, 16, 20, 32, 40, and 52</time_frame>
        <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Nail Psoriasis Severity Index (NAPSI) Score Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
          <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=40,38,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8" spread="20.58" lower_limit="0.00" upper_limit="5.58"/>
                    <measurement group_id="O2" value="26.2" spread="16.97" lower_limit="0.00" upper_limit="3.35"/>
                    <measurement group_id="O3" value="28.7" spread="21.90" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O4" value="25.2" spread="16.37" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=39,38,15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="19.45" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="23.6" spread="17.29" lower_limit="0.00" upper_limit="5.64"/>
                    <measurement group_id="O3" value="28.6" spread="23.66" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O4" value="30.7" spread="18.48" lower_limit="0.00" upper_limit="16.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=38,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2" spread="19.14" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="19.8" spread="18.30" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="30.3" spread="23.86" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="28.9" spread="20.54" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=37,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.9" spread="18.70" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="17.2" spread="16.94" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="28.6" spread="24.02" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="30.1" spread="19.08" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=37,37,14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.6" spread="19.59" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="15.5" spread="16.69" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="16.2" spread="18.48" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="17.1" spread="12.69" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=36,36,13,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" spread="18.65" lower_limit="0.00" upper_limit="3.68"/>
                    <measurement group_id="O2" value="14.9" spread="16.01" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="15.7" spread="15.82" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="14.5" spread="13.93" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=31,34,12,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="20.22"/>
                    <measurement group_id="O2" value="13.2" spread="17.96"/>
                    <measurement group_id="O3" value="13.8" spread="18.54"/>
                    <measurement group_id="O4" value="10.5" spread="12.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail was divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
        <time_frame>Baseline and weeks 8, 16, 20, 32, 40, and 52</time_frame>
        <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NAPSI Over Time Through Week 52 in Participants With Nail Psoriasis at Baseline</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail was divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
          <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=39,38,15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.60" spread="1.416" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="-2.76" spread="1.434" lower_limit="0.00" upper_limit="5.64"/>
                    <measurement group_id="O3" value="2.17" spread="2.282" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O4" value="2.64" spread="2.283" lower_limit="0.00" upper_limit="16.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=38,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.38" spread="1.927" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="-6.63" spread="1.936" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="2.04" spread="3.151" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="0.84" spread="3.082" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=37,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.68" spread="1.886" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="-9.18" spread="1.884" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="0.48" spread="3.079" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="2.04" spread="2.999" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=37,37,14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.02" spread="2.350" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="-11.31" spread="2.350" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="-11.81" spread="3.834" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="-12.61" spread="3.788" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=36,36,13,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.31" spread="2.365" lower_limit="0.00" upper_limit="3.68"/>
                    <measurement group_id="O2" value="-11.94" spread="2.359" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="-13.42" spread="3.876" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="-14.19" spread="3.842" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=31,34,12,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.13" spread="2.689"/>
                    <measurement group_id="O2" value="-13.55" spread="2.651"/>
                    <measurement group_id="O3" value="-15.08" spread="4.387"/>
                    <measurement group_id="O4" value="-17.89" spread="4.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52</title>
        <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported. The total number of affected FINGER nails was reported.</description>
        <time_frame>Baseline and Weeks 8, 16, 20, 32, 40, and 52</time_frame>
        <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Affected Nails in Participants With Nail Psoriasis at Baseline Over Time Through Week 52</title>
          <description>Nail psoriasis is evaluated by the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Total number psoriasis affected nails (presence of psoriatic manifestations on the nail matrix/nail bed) were assessed and reported. The total number of affected FINGER nails was reported.</description>
          <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
          <units>nails</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=40,38,18,18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="3.06" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="7.3" spread="3.21" lower_limit="0.00" upper_limit="5.64"/>
                    <measurement group_id="O3" value="8.1" spread="2.97" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O4" value="7.4" spread="3.45" lower_limit="0.00" upper_limit="16.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=39,38,15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="3.07" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="7.2" spread="3.61" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="7.3" spread="3.58" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="7.9" spread="3.20" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=38,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="3.53" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="6.6" spread="3.57" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="7.9" spread="3.82" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="7.6" spread="3.56" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=37,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="3.84" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="6.0" spread="3.84" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="7.4" spread="3.93" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="7.9" spread="3.08" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=37,37,14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="3.92" lower_limit="0.00" upper_limit="3.68"/>
                    <measurement group_id="O2" value="5.5" spread="3.85" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="6.1" spread="3.95" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="7.6" spread="3.72" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=36,36,13,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.60"/>
                    <measurement group_id="O2" value="5.4" spread="4.08"/>
                    <measurement group_id="O3" value="6.3" spread="4.39"/>
                    <measurement group_id="O4" value="5.8" spread="4.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=31,34,12,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.67"/>
                    <measurement group_id="O2" value="4.4" spread="4.23"/>
                    <measurement group_id="O3" value="4.6" spread="4.12"/>
                    <measurement group_id="O4" value="4.4" spread="3.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in NAPSI Over Time Through Week 52</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
        <time_frame>Baseline and weeks 8, 16, 20, 32, 40, and 52</time_frame>
        <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 0hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in NAPSI Over Time Through Week 52</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis.</description>
          <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8 (n=39,38,15,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.59" spread="8.473" lower_limit="0.00" upper_limit="3.51"/>
                    <measurement group_id="O2" value="-8.81" spread="8.585" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="5.28" spread="13.661" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="25.40" spread="13.662" lower_limit="0.00" upper_limit="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=38,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.31" spread="10.552" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="-14.91" spread="10.600" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="-3.26" spread="17.257" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="18.43" spread="16.869" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=37,38,14,15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-51.97" spread="8.748" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="-25.10" spread="8.715" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="-8.87" spread="14.276" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="13.72" spread="13.869" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=37,37,14,14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.44" spread="10.256" lower_limit="0.00" upper_limit="3.68"/>
                    <measurement group_id="O2" value="-25.27" spread="10.247" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="-50.20" spread="16.734" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="-45.83" spread="16.481" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=36,36,13,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.68" spread="9.243"/>
                    <measurement group_id="O2" value="-37.40" spread="9.208"/>
                    <measurement group_id="O3" value="-47.17" spread="15.143"/>
                    <measurement group_id="O4" value="-58.60" spread="14.988"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=31,34,12,13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71.40" spread="10.891"/>
                    <measurement group_id="O2" value="-51.71" spread="10.636"/>
                    <measurement group_id="O3" value="-56.08" spread="17.621"/>
                    <measurement group_id="O4" value="-45.67" spread="17.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With NAPSI75 Response Over Time Through Week 52</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.</description>
        <time_frame>Weeks 8, 16, 20, 32, 40, and 52</time_frame>
        <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With NAPSI75 Response Over Time Through Week 52</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 75 response was defined as at least a 75% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 75 response is reported.</description>
          <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O2" value="10.53" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O3" value="5.56" lower_limit="0.00" upper_limit="16.14"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.00" lower_limit="7.60" upper_limit="32.40"/>
                    <measurement group_id="O2" value="15.79" lower_limit="4.20" upper_limit="27.38"/>
                    <measurement group_id="O3" value="11.11" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="5.56" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="13.16" lower_limit="2.41" upper_limit="23.91"/>
                    <measurement group_id="O3" value="11.11" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.50" lower_limit="37.02" upper_limit="67.98"/>
                    <measurement group_id="O2" value="28.95" lower_limit="14.53" upper_limit="43.37"/>
                    <measurement group_id="O3" value="27.78" lower_limit="7.09" upper_limit="48.47"/>
                    <measurement group_id="O4" value="16.67" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.00" lower_limit="50.22" upper_limit="79.78"/>
                    <measurement group_id="O2" value="34.21" lower_limit="19.13" upper_limit="49.29"/>
                    <measurement group_id="O3" value="33.33" lower_limit="11.56" upper_limit="55.11"/>
                    <measurement group_id="O4" value="33.33" lower_limit="11.56" upper_limit="55.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.50" lower_limit="37.02" upper_limit="67.98"/>
                    <measurement group_id="O2" value="47.37" lower_limit="31.49" upper_limit="63.24"/>
                    <measurement group_id="O3" value="38.89" lower_limit="16.37" upper_limit="61.41"/>
                    <measurement group_id="O4" value="38.89" lower_limit="16.37" upper_limit="61.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With NAPSI100 Response Over Time Through Week 52</title>
        <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.</description>
        <time_frame>Weeks 8, 16, 20, 32, 40, and 52</time_frame>
        <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With NAPSI100 Response Over Time Through Week 52</title>
          <description>The NAPSI quantifies severity of nail psoriasis by evaluating the presence or absence of psoriatic manifestations on the nail matrix (pitting, leukonychia, red spots on lulunea, crumbling) and nail bed (onycholysis, splinter hemorrhages, subungual hyperkeratosis, oil drop [salmon patch dyschromia]). Each finger nail divided with imaginary lines into quadrants and scored for both nail matrix and nail bed psoriasis (range from 0 [absence of psoriasis] to 4 [presence of psoriasis in all 4 quadrants]). The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 to 80. Higher scores represents more severe psoriasis. NAPSI 100 response was defined as at least a 100% reduction in NAPSI relative to Baseline. Percentage of participants with NAPSI 100 response is reported.</description>
          <population>Number of participants analyzed signifies the FAS participants (randomized and received at least 1 dose of investigational drug) who were evaluable (had nail psoriasis at Baseline and at least 1 measurement during follow up) for this measure. n=number of evaluable participants at the specified time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O2" value="5.26" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="0.00" upper_limit="11.75"/>
                    <measurement group_id="O2" value="5.26" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="11.11" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="5.56" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.50" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O2" value="10.53" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O3" value="11.11" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.50" lower_limit="13.66" upper_limit="41.34"/>
                    <measurement group_id="O2" value="13.16" lower_limit="2.41" upper_limit="23.91"/>
                    <measurement group_id="O3" value="11.11" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="5.56" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="15.79" lower_limit="4.20" upper_limit="27.38"/>
                    <measurement group_id="O3" value="11.11" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="16.67" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.00" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="31.58" lower_limit="16.80" upper_limit="46.36"/>
                    <measurement group_id="O3" value="16.67" lower_limit="0.00" upper_limit="33.88"/>
                    <measurement group_id="O4" value="16.67" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Itch Severity Item (ISI) Score Over Time Through Week 52</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Itch Severity Item (ISI) Score Over Time Through Week 52</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends for post baseline time points. Baseline ISI is average of scores on 7 days prior to start of study treatment.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=88,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.66" spread="2.586" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="5.10" spread="2.679" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="5.22" spread="2.501" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="5.75" spread="2.679" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=87,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" spread="2.043" lower_limit="0.00" upper_limit="11.75"/>
                    <measurement group_id="O2" value="3.49" spread="2.669" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="5.45" spread="2.791" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="4.95" spread="2.731" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=88,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="2.061" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O2" value="2.68" spread="2.322" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O3" value="5.23" spread="2.715" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="5.12" spread="2.491" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.47" spread="1.900" lower_limit="13.66" upper_limit="41.34"/>
                    <measurement group_id="O2" value="2.41" spread="2.283" lower_limit="2.41" upper_limit="23.91"/>
                    <measurement group_id="O3" value="4.75" spread="2.677" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="4.97" spread="2.978" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.24" spread="1.565" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="2.13" spread="2.323" lower_limit="4.20" upper_limit="27.38"/>
                    <measurement group_id="O3" value="4.00" spread="2.621" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="5.00" spread="2.938" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="1.782" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="2.01" spread="2.367" lower_limit="16.80" upper_limit="46.36"/>
                    <measurement group_id="O3" value="3.89" spread="2.391" lower_limit="0.00" upper_limit="33.88"/>
                    <measurement group_id="O4" value="5.13" spread="2.811" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=83,84,38,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.564"/>
                    <measurement group_id="O2" value="2.01" spread="2.326"/>
                    <measurement group_id="O3" value="1.95" spread="2.253"/>
                    <measurement group_id="O4" value="2.11" spread="2.227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=838238,37</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="1.273"/>
                    <measurement group_id="O2" value="2.07" spread="2.382"/>
                    <measurement group_id="O3" value="1.24" spread="1.747"/>
                    <measurement group_id="O4" value="1.51" spread="2.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="1.145"/>
                    <measurement group_id="O2" value="2.30" spread="2.283"/>
                    <measurement group_id="O3" value="1.49" spread="2.181"/>
                    <measurement group_id="O4" value="1.53" spread="2.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="2.074"/>
                    <measurement group_id="O2" value="2.55" spread="2.516"/>
                    <measurement group_id="O3" value="1.89" spread="2.482"/>
                    <measurement group_id="O4" value="2.36" spread="2.380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in ISI Score Over Time Through Week 52</title>
        <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
        <time_frame>Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in ISI Score Over Time Through Week 52</title>
          <description>ISI assessed severity of itch (pruritus) due to psoriasis. ISI is a single item, horizontal numeric rating scale. Participants were asked to rate &quot;your worst itching due to psoriasis over the past 24 hours&quot; on a numeric rating scale anchored by the terms &quot;No itching&quot; (0) and &quot;Worst possible itching&quot; (10) at the ends.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=86,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.50" spread="0.219" lower_limit="0.00" upper_limit="11.75"/>
                    <measurement group_id="O2" value="-1.76" spread="0.218" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="0.12" spread="0.306" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-0.64" spread="0.314" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=87,88,43,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="0.226" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O2" value="-2.60" spread="0.224" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O3" value="-0.03" spread="0.319" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-0.47" spread="0.325" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=84,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.93" spread="0.232" lower_limit="13.66" upper_limit="41.34"/>
                    <measurement group_id="O2" value="-2.88" spread="0.228" lower_limit="2.41" upper_limit="23.91"/>
                    <measurement group_id="O3" value="-0.50" spread="0.331" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-0.46" spread="0.337" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=83,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="0.237" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="-3.16" spread="0.233" lower_limit="4.20" upper_limit="27.38"/>
                    <measurement group_id="O3" value="-1.15" spread="0.338" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-0.44" spread="0.344" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=83,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.21" spread="0.232" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="-3.28" spread="0.229" lower_limit="16.80" upper_limit="46.36"/>
                    <measurement group_id="O3" value="-1.30" spread="0.335" lower_limit="0.00" upper_limit="33.88"/>
                    <measurement group_id="O4" value="-0.33" spread="0.337" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=82,84,38,38)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.32" spread="0.219"/>
                    <measurement group_id="O2" value="-3.28" spread="0.216"/>
                    <measurement group_id="O3" value="-3.22" spread="0.318"/>
                    <measurement group_id="O4" value="-3.36" spread="0.320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=82,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.51" spread="0.220"/>
                    <measurement group_id="O2" value="-3.17" spread="0.219"/>
                    <measurement group_id="O3" value="-4.01" spread="0.322"/>
                    <measurement group_id="O4" value="-4.04" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=80,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.39" spread="0.224"/>
                    <measurement group_id="O2" value="-2.98" spread="0.222"/>
                    <measurement group_id="O3" value="-3.81" spread="0.328"/>
                    <measurement group_id="O4" value="-3.89" spread="0.331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=79,78,36,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.91" spread="0.272"/>
                    <measurement group_id="O2" value="-2.71" spread="0.272"/>
                    <measurement group_id="O3" value="-3.47" spread="0.401"/>
                    <measurement group_id="O4" value="-3.11" spread="0.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Actual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Actual Dermatology Life Quality Index (DLQI) Score Over Time Through Week 52</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1" spread="7.17" lower_limit="0.00" upper_limit="11.75"/>
                    <measurement group_id="O2" value="13.5" spread="7.29" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="12.5" spread="6.82" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="12.1" spread="6.92" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="5.31" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O2" value="10.0" spread="6.20" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O3" value="12.6" spread="7.34" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="10.4" spread="5.97" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=86,88,42,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="5.00" lower_limit="13.66" upper_limit="41.34"/>
                    <measurement group_id="O2" value="8.2" spread="5.46" lower_limit="2.41" upper_limit="23.91"/>
                    <measurement group_id="O3" value="12.4" spread="7.99" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="10.3" spread="5.39" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="5.49" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="7.5" spread="5.89" lower_limit="4.20" upper_limit="27.38"/>
                    <measurement group_id="O3" value="11.2" spread="7.25" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="9.9" spread="6.66" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="4.47" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="6.7" spread="6.16" lower_limit="16.80" upper_limit="46.36"/>
                    <measurement group_id="O3" value="11.1" spread="7.11" lower_limit="0.00" upper_limit="33.88"/>
                    <measurement group_id="O4" value="10.2" spread="6.86" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="4.70"/>
                    <measurement group_id="O2" value="6.2" spread="5.62"/>
                    <measurement group_id="O3" value="10.7" spread="7.20"/>
                    <measurement group_id="O4" value="10.5" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=82,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="4.46"/>
                    <measurement group_id="O2" value="5.4" spread="5.50"/>
                    <measurement group_id="O3" value="6.2" spread="4.80"/>
                    <measurement group_id="O4" value="6.4" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="4.39"/>
                    <measurement group_id="O2" value="5.1" spread="5.31"/>
                    <measurement group_id="O3" value="4.7" spread="5.42"/>
                    <measurement group_id="O4" value="5.0" spread="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="4.37"/>
                    <measurement group_id="O2" value="5.9" spread="5.44"/>
                    <measurement group_id="O3" value="4.6" spread="5.07"/>
                    <measurement group_id="O4" value="4.1" spread="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="5.83"/>
                    <measurement group_id="O2" value="6.5" spread="6.25"/>
                    <measurement group_id="O3" value="4.7" spread="5.85"/>
                    <measurement group_id="O4" value="6.0" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DLQI Score Over Time Through Week 52</title>
        <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
        <time_frame>Baseline and weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DLQI Score Over Time Through Week 52</title>
          <description>The DLQI is a 10 item general dermatology questionnaire that assesses health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI item response options are rated by the participant from 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=88,86,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.98" spread="0.455" lower_limit="0.00" upper_limit="11.75"/>
                    <measurement group_id="O2" value="-3.26" spread="0.458" lower_limit="0.00" upper_limit="12.36"/>
                    <measurement group_id="O3" value="-0.20" spread="0.644" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-2.27" spread="0.659" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=86,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.96" spread="0.492" lower_limit="5.72" upper_limit="29.28"/>
                    <measurement group_id="O2" value="-5.11" spread="0.488" lower_limit="0.77" upper_limit="20.28"/>
                    <measurement group_id="O3" value="0.17" spread="0.700" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-2.26" spread="0.712" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=85,88,40,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.52" spread="0.594" lower_limit="13.66" upper_limit="41.34"/>
                    <measurement group_id="O2" value="-5.83" spread="0.587" lower_limit="2.41" upper_limit="23.91"/>
                    <measurement group_id="O3" value="-1.00" spread="0.852" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-2.70" spread="0.868" lower_limit="0.00" upper_limit="16.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=84,88,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.59" spread="0.618" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="-6.64" spread="0.609" lower_limit="4.20" upper_limit="27.38"/>
                    <measurement group_id="O3" value="-0.76" spread="0.891" lower_limit="0.00" upper_limit="25.63"/>
                    <measurement group_id="O4" value="-2.44" spread="0.904" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.03" spread="0.618" lower_limit="15.80" upper_limit="44.20"/>
                    <measurement group_id="O2" value="-7.00" spread="0.611" lower_limit="16.80" upper_limit="46.36"/>
                    <measurement group_id="O3" value="-1.15" spread="0.899" lower_limit="0.00" upper_limit="33.88"/>
                    <measurement group_id="O4" value="-2.22" spread="0.905" lower_limit="0.00" upper_limit="33.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=82,84,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.36" spread="0.562"/>
                    <measurement group_id="O2" value="-7.78" spread="0.555"/>
                    <measurement group_id="O3" value="-5.84" spread="0.819"/>
                    <measurement group_id="O4" value="-6.30" spread="0.821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.05" spread="0.565"/>
                    <measurement group_id="O2" value="-8.07" spread="0.562"/>
                    <measurement group_id="O3" value="-7.44" spread="0.828"/>
                    <measurement group_id="O4" value="-7.94" spread="0.837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.56" spread="0.563"/>
                    <measurement group_id="O2" value="-7.32" spread="0.559"/>
                    <measurement group_id="O3" value="-7.61" spread="0.826"/>
                    <measurement group_id="O4" value="-8.28" spread="0.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.63" spread="0.679"/>
                    <measurement group_id="O2" value="-6.63" spread="0.681"/>
                    <measurement group_id="O3" value="-7.42" spread="1.012"/>
                    <measurement group_id="O4" value="-6.37" spread="1.010"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Patient Global Assessment (PtGA) Response of &quot;Clear&quot; or &quot;Almost Clear&quot; Over Time Through Week 52</title>
        <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe). the percentage of participants with scores of 0 (clear) and 1 (almost clear) are reported.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, 20, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Patient Global Assessment (PtGA) Response of &quot;Clear&quot; or &quot;Almost Clear&quot; Over Time Through Week 52</title>
          <description>The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear [no psoriasis]; 1=almost clear; 2=mild; 3=moderate; 4=severe). the percentage of participants with scores of 0 (clear) and 1 (almost clear) are reported.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo. NRI method (participants with missing values considered as non-responders) was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O2" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O3" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.78" lower_limit="2.24" upper_limit="13.31"/>
                    <measurement group_id="O2" value="5.68" lower_limit="0.85" upper_limit="10.52"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.22" lower_limit="22.57" upper_limit="41.88"/>
                    <measurement group_id="O2" value="19.32" lower_limit="11.07" upper_limit="27.57"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.56" lower_limit="35.27" upper_limit="55.84"/>
                    <measurement group_id="O2" value="27.27" lower_limit="17.97" upper_limit="36.58"/>
                    <measurement group_id="O3" value="2.27" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.00" lower_limit="NA" upper_limit="NA">It is because the calculation method is based on normal approximation which assumes a big sample size, but n=0 at these weeks. Hence, it's not appropriate to use normal approximation to estimate the CI's.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.56" lower_limit="45.29" upper_limit="65.82"/>
                    <measurement group_id="O2" value="34.09" lower_limit="24.19" upper_limit="43.99"/>
                    <measurement group_id="O3" value="9.09" lower_limit="0.60" upper_limit="17.59"/>
                    <measurement group_id="O4" value="4.55" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.22" lower_limit="41.90" upper_limit="62.54"/>
                    <measurement group_id="O2" value="31.82" lower_limit="22.09" upper_limit="41.55"/>
                    <measurement group_id="O3" value="18.18" lower_limit="6.79" upper_limit="29.58"/>
                    <measurement group_id="O4" value="13.64" lower_limit="3.50" upper_limit="23.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.67" lower_limit="46.43" upper_limit="66.90"/>
                    <measurement group_id="O2" value="34.09" lower_limit="24.19" upper_limit="43.99"/>
                    <measurement group_id="O3" value="45.45" lower_limit="30.74" upper_limit="60.17"/>
                    <measurement group_id="O4" value="31.82" lower_limit="18.06" upper_limit="45.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.22" lower_limit="41.90" upper_limit="62.54"/>
                    <measurement group_id="O2" value="34.09" lower_limit="24.19" upper_limit="43.99"/>
                    <measurement group_id="O3" value="50.00" lower_limit="35.23" upper_limit="64.77"/>
                    <measurement group_id="O4" value="40.91" lower_limit="26.38" upper_limit="55.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.11" lower_limit="40.78" upper_limit="61.44"/>
                    <measurement group_id="O2" value="26.14" lower_limit="16.96" upper_limit="35.32"/>
                    <measurement group_id="O3" value="47.73" lower_limit="32.97" upper_limit="62.49"/>
                    <measurement group_id="O4" value="29.55" lower_limit="16.06" upper_limit="43.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.</description>
        <time_frame>Baseline, Weeks 16, 32, 40, 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Utility Score Over Time Through Week 52</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.784" spread="0.2088" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="0.797" spread="0.1991" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="0.779" spread="0.1803" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="0.741" spread="0.2183" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,83,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.957" spread="0.0778" lower_limit="2.24" upper_limit="13.31"/>
                    <measurement group_id="O2" value="0.930" spread="0.1226" lower_limit="0.85" upper_limit="10.52"/>
                    <measurement group_id="O3" value="0.905" spread="0.1191" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.817" spread="0.2108" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.955" spread="0.0796" lower_limit="22.57" upper_limit="41.88"/>
                    <measurement group_id="O2" value="0.904" spread="0.1368" lower_limit="11.07" upper_limit="27.57"/>
                    <measurement group_id="O3" value="0.960" spread="0.0739" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.917" spread="0.1477" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.950" spread="0.0940" lower_limit="35.27" upper_limit="55.84"/>
                    <measurement group_id="O2" value="0.918" spread="0.1177" lower_limit="17.97" upper_limit="36.58"/>
                    <measurement group_id="O3" value="0.954" spread="0.0776" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.938" spread="0.1125" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.938" spread="0.1303" lower_limit="45.29" upper_limit="65.82"/>
                    <measurement group_id="O2" value="0.893" spread="0.1719" lower_limit="24.19" upper_limit="43.99"/>
                    <measurement group_id="O3" value="0.941" spread="0.1118" lower_limit="0.60" upper_limit="17.59"/>
                    <measurement group_id="O4" value="0.887" spread="0.1626" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D - Utility Score Over Time Through Week 52</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.</description>
        <time_frame>Baseline and weeks 16, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D - Utility Score Over Time Through Week 52</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a worse health state.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 (n=84,83,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" spread="0.2164" lower_limit="2.24" upper_limit="13.31"/>
                    <measurement group_id="O2" value="0.128" spread="0.2108" lower_limit="0.85" upper_limit="10.52"/>
                    <measurement group_id="O3" value="0.105" spread="0.1824" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.074" spread="0.2391" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.170" spread="0.2092" lower_limit="22.57" upper_limit="41.88"/>
                    <measurement group_id="O2" value="0.109" spread="0.2347" lower_limit="11.07" upper_limit="27.57"/>
                    <measurement group_id="O3" value="0.160" spread="0.1904" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.173" spread="0.2202" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.168" spread="0.2159" lower_limit="35.27" upper_limit="55.84"/>
                    <measurement group_id="O2" value="0.120" spread="0.2322" lower_limit="17.97" upper_limit="36.58"/>
                    <measurement group_id="O3" value="0.159" spread="0.1937" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="0.192" spread="0.2103" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.156" spread="0.2071" lower_limit="45.29" upper_limit="65.82"/>
                    <measurement group_id="O2" value="0.101" spread="0.2477" lower_limit="24.19" upper_limit="43.99"/>
                    <measurement group_id="O3" value="0.147" spread="0.2136" lower_limit="0.60" upper_limit="17.59"/>
                    <measurement group_id="O4" value="0.142" spread="0.2328" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Baseline and Weeks 16, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Euro Quality of Life 5 Dimensions (EQ-5D) - Visual Analog Scale (VAS) Over Time Through Week 52</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=90,88,44,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="24.90" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O2" value="69.5" spread="19.84" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O3" value="66.4" spread="23.09" lower_limit="NA" upper_limit="NA"/>
                    <measurement group_id="O4" value="67.4" spread="21.92" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=84,83,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.7" spread="15.30" lower_limit="2.24" upper_limit="13.31"/>
                    <measurement group_id="O2" value="78.9" spread="15.41" lower_limit="0.85" upper_limit="10.52"/>
                    <measurement group_id="O3" value="72.3" spread="22.04" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="68.4" spread="20.20" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.5" spread="16.17" lower_limit="22.57" upper_limit="41.88"/>
                    <measurement group_id="O2" value="82.4" spread="16.00" lower_limit="11.07" upper_limit="27.57"/>
                    <measurement group_id="O3" value="85.2" spread="14.36" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="81.7" spread="17.25" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.5" spread="14.45" lower_limit="35.27" upper_limit="55.84"/>
                    <measurement group_id="O2" value="83.0" spread="14.35" lower_limit="17.97" upper_limit="36.58"/>
                    <measurement group_id="O3" value="83.5" spread="16.86" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="81.9" spread="16.03" lower_limit="NA" upper_limit="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.5" spread="17.13" lower_limit="45.29" upper_limit="65.82"/>
                    <measurement group_id="O2" value="80.0" spread="18.40" lower_limit="24.19" upper_limit="43.99"/>
                    <measurement group_id="O3" value="85.0" spread="13.58" lower_limit="0.60" upper_limit="17.59"/>
                    <measurement group_id="O4" value="80.7" spread="19.20" lower_limit="0.00" upper_limit="10.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
        <time_frame>Baseline and weeks 16, 32, 40, and 52</time_frame>
        <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in EQ-5D - Visual Analog Scale (VAS) Over Time Through Week 52</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 millimeter (mm) (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.</description>
          <population>The full analysis population included all participants who were randomized to the study and received at least 1 dose of tofacitinib or placebo; number of participants analyzed was the evaluable participants for the specific criteria; n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16 (n=84,83,38,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5" spread="25.23" lower_limit="2.24" upper_limit="13.31"/>
                    <measurement group_id="O2" value="8.8" spread="21.15" lower_limit="0.85" upper_limit="10.52"/>
                    <measurement group_id="O3" value="2.6" spread="22.17" lower_limit="0.00" upper_limit="6.68"/>
                    <measurement group_id="O4" value="-0.6" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=83,82,38,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="25.92"/>
                    <measurement group_id="O2" value="13.1" spread="22.36"/>
                    <measurement group_id="O3" value="15.4" spread="23.50"/>
                    <measurement group_id="O4" value="12.2" spread="23.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=81,81,37,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" spread="27.07"/>
                    <measurement group_id="O2" value="13.3" spread="22.31"/>
                    <measurement group_id="O3" value="14.3" spread="23.19"/>
                    <measurement group_id="O4" value="11.8" spread="24.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=80,78,35,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="26.08"/>
                    <measurement group_id="O2" value="9.9" spread="24.54"/>
                    <measurement group_id="O3" value="15.2" spread="22.96"/>
                    <measurement group_id="O4" value="10.7" spread="21.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-16</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-16</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with AEs(All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with SAEs(All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-52</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment-Emergent All Causalities Adverse Events (AEs) During Week 0-52</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both SAEs and non-SAEs.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Participants with AEs (All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants with SAEs(All Causalities)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Participants Discontinued due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-16</title>
        <description>Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) &lt;1.0 X 10^9/L (1000/mm^3); 2 sequential absolute lymphocyte counts &lt;0.5 X 10^9/L; 2 sequential hemoglobin values &lt;9.0 g/dL and/or decreases of &gt;30% from baseline value; 2 sequential platelet counts &lt;75 X 10^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine &gt;50% and an increase in serum creatinine &gt;0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations &gt;10X ULN.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-16</title>
          <description>Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) &lt;1.0 X 10^9/L (1000/mm^3); 2 sequential absolute lymphocyte counts &lt;0.5 X 10^9/L; 2 sequential hemoglobin values &lt;9.0 g/dL and/or decreases of &gt;30% from baseline value; 2 sequential platelet counts &lt;75 X 10^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine &gt;50% and an increase in serum creatinine &gt;0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations &gt;10X ULN.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Sequential absolute neutrophil count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential absolute lymphocyte count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential AST or ALT reason #1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential AST or ALT reason #2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential serum creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 sequential creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-52</title>
        <description>Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) &lt;1.0 X 10^9/L (1000/mm^3); 2 sequential absolute lymphocyte counts &lt;0.5 X 10^9/L; 2 sequential hemoglobin values &lt;9.0 g/dL and/or decreases of &gt;30% from baseline value; 2 sequential platelet counts &lt;75 X 10^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine &gt;50% and an increase in serum creatinine &gt;0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations &gt;10X ULN.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Laboratory Values Meeting Protocol Criteria for Discontinuation During Week 0-52</title>
          <description>Study drugs were to be discontinued and the participant withdrawn for: 2 sequential absolute neutrophil counts (ANC) &lt;1.0 X 10^9/L (1000/mm^3); 2 sequential absolute lymphocyte counts &lt;0.5 X 10^9/L; 2 sequential hemoglobin values &lt;9.0 g/dL and/or decreases of &gt;30% from baseline value; 2 sequential platelet counts &lt;75 X 10^9/L; 2 sequential AST or ALT elevations ≥3X ULN with at least 1 total bilirubin value ≥2X ULN (reason #1); 2 sequential AST or ALT elevations ≥5X ULN regardless of total bilirubin or accompanying signs or symptoms (reason #2); 2 sequential increases in serum creatinine &gt;50% and an increase in serum creatinine &gt;0.5 mg/dL over the average of screening and baseline values; 2 sequential CK elevations &gt;10X ULN.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 Sequential absolute neutrophil count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential absolute lymphocyte count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential AST or ALT reason #1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential AST or ALT reason #2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Sequential serum creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 sequential creatine kinase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-16</title>
        <description>Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (&lt;)40 or greater than (&gt;)120 beats per minute (bpm), heart rate less than (&lt;)40 or greater than (&gt;)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (&gt;=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP &lt;90 mmHg, sitting diastolic blood pressure (DBP) &gt;=20 mmHg change from baseline or sitting DBP &lt;50 mmHg.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo; n=number of participants evaluated against criteria.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-16</title>
          <description>Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (&lt;)40 or greater than (&gt;)120 beats per minute (bpm), heart rate less than (&lt;)40 or greater than (&gt;)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (&gt;=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP &lt;90 mmHg, sitting diastolic blood pressure (DBP) &gt;=20 mmHg change from baseline or sitting DBP &lt;50 mmHg.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo; n=number of participants evaluated against criteria.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting SBP &lt;90 mmHg (n=87,88,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP &lt;50 mmHg (n=87,88,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate &lt;40 or &gt;120 bpm (n=73,74,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate &lt;40 or &gt;120 bpm (n=84,85,82)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP max Increase &gt;=30 Hg(n=87,88,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP max Increase &gt;=20 mmHg(n=87,88,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP max Decrease &gt;=30 mmHg(n=87,88,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP max Decrease &gt;=20 mmHg(n=87,88,86)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-52</title>
        <description>Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (&lt;)40 or greater than (&gt;)120 beats per minute (bpm), heart rate less than (&lt;)40 or greater than (&gt;)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (&gt;=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP &lt;90 mmHg, sitting diastolic blood pressure (DBP) &gt;=20 mmHg change from baseline or sitting DBP &lt;50 mmHg.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo; n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vital Sign Values Meeting the Criteria for Potential Clinical Concern During Week 0-52</title>
          <description>Vital signs assessment included pulse rate and blood pressure. Criteria for vital sign values meeting potential clinical concern included: pulse rate less than (&lt;)40 or greater than (&gt;)120 beats per minute (bpm), heart rate less than (&lt;)40 or greater than (&gt;)120 bpm; sitting systolic blood pressure (SBP) of greater than or equal to (&gt;=)30 millimeters of mercury (mmHg) change from baseline or sitting SBP &lt;90 mmHg, sitting diastolic blood pressure (DBP) &gt;=20 mmHg change from baseline or sitting DBP &lt;50 mmHg.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo; n=number of evaluable participants at the specified time point.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sitting SBP &lt;90 mmHg (n=87,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP &lt;50 mmHg (n=87,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Rate &lt;40 or &gt;120 bpm (n=74,75,35,34)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate &lt;40 or &gt;120 bpm (n=86,85,42,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP max Increase &gt;=30 Hg(n=87,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP max Increase &gt;=20 mmHg(n=87,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting SBP max Decrease &gt;=30 mmHg(n=87,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sitting DBP max Decrease &gt;=20 mmHg(n=87,88,44,42)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-16</title>
        <description>CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty [PTCA], percutaneous coronary intervention [PCI], coronary bypass grafting [CABG], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-16</title>
          <description>CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty [PTCA], percutaneous coronary intervention [PCI], coronary bypass grafting [CABG], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebrovascular Accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Revascularization Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Ischemic Heart Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-CV Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-52</title>
        <description>CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty [PTCA], percutaneous coronary intervention [PCI], coronary bypass grafting [CABG], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.</description>
        <time_frame>Baseline up to Week 52</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Participants With Adjudicated Cardiovascular (CV) Endpoints Reported During Week 0-52</title>
          <description>CV event categories included: cerebrovascular accident (CVA), coronary revascularization procedure (percutaneous transluminal coronary angioplasty [PTCA], percutaneous coronary intervention [PCI], coronary bypass grafting [CABG], heart failure, major adverse cardiac events (MACE), myocardial infarction (MI), new ischemic heart disease, peripheral vascular disease (first diagnosis). MACE included any MI, CVA (stroke or transient ischemic attack), or CV death.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cerebrovascular Accident</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coronary Revascularization Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MACE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial Infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Ischemic Heart Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peripheral Vascular Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-CV Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adjudicated Malignancy Events Reported During Week 0-16</title>
        <description>As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.</description>
        <time_frame>Baseline to Week 16</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Malignancy Events Reported During Week 0-16</title>
          <description>As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Adjudicated Malignancy Events Reported During Week 0-52</title>
        <description>As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.</description>
        <time_frame>Baseline to Week 52</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>Tofacitinib 10 mg</title>
            <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O2">
            <title>Tofacitinib 5 mg</title>
            <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
          </group>
          <group group_id="O3">
            <title>Placebo to Tofacitinib 10 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
          </group>
          <group group_id="O4">
            <title>Placebo to Tofacitinib 5 mg</title>
            <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adjudicated Malignancy Events Reported During Week 0-52</title>
          <description>As part of AE monitoring, potential malignancy events were adjudicated and centrally reviewed by a safety committee.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of tofacitinib or placebo.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Week 52</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one participant and as non-serious in another participant, or one participant may have experienced both a serious and a non-serious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tofacitinib 10 mg</title>
          <description>Participants received tofacitinib 10 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
        </group>
        <group group_id="E2">
          <title>Tofacitinib 5 mg</title>
          <description>Participants received tofacitinib 5 mg tablet orally twice daily (approximately 12 hours apart) up to Week 52.</description>
        </group>
        <group group_id="E3">
          <title>Placebo to Tofacitinib 10 mg</title>
          <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 10 mg twice daily up to Week 52.</description>
        </group>
        <group group_id="E4">
          <title>Placebo to Tofacitinib 5 mg</title>
          <description>Participants received placebo tablet orally twice daily until Week 16, followed by tofacitinib 5 mg twice daily up to Week 52.</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Participants received placebo tablets orally twice daily up to Week 16. At Week 16, participants in this group were automatically advanced to their second treatment of tofacitinib 5 mg or 10 mg tablet orally twice daily, which was pre-determined at randomization (44 participants assigned to Placebo to 5 mg, 44 participants assigned to Placebo to 10 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <description>This event is limited to female participants.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <description>This event is limited to female participants.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomenorrhoea</sub_title>
                <description>This event is limited to female participants.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <description>This event is limited to female participants.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

